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1. Introduction  
 
 
1.1 Chemical Genetics 
 
1.1.1 Definition 
 
Chemical genetics is the study of the function of gene products using 
perturbation by small molecules. A more detailed explanation of certain terms 
within the given definition shall facilitate better understanding. 
Chemical genetics is often used interchangeably with the term chemical 
genomics. In most cases both mean the same field and scientific approach. 
However, there is a certain distinction very similar to the difference between 
the fields of genetics and genomics. In general, the suffix -ome, such as in 
genome, proteome, or metabolome, indicates the entire pool of a certain type 
of molecules within a biological system. Omics aims at the global study of the 
entire pool, e.g. the global transcription analysis to study structural and 
functional differences between two cell types. In the analogous sense, the 
extension from chemical genetics to chemical genomics is the aim to identify 
a specific inhibitor for each gene product in the human genome (Schreiber, 
2005).   
In chemical biology and medicinal chemistry small molecules are used to 
inhibit specific protein functions. Chemical biology applies small molecules to 
study biological phenomena by identifying the protein targets that cause or 
prevent a biological effect. The aim of medicinal chemistry is to identify 
selective and potent inhibitors of protein targets that cause a pathological 
outcome. This process certainly includes the study of the pathological 
mechanism, as well as the mechanism of action of the inhibitor. Both, 
however, contain the three main components of chemical genetics which are  
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the synthetic generation and expansion of small molecule libraries, 
development of screening assays, and target identification and validation.   
Next, the meaning of gene product within the above definition of chemical 
genetics shall be explained. A gene is the sequence of nucleic acids within 
the DNA encoding a protein. The DNA is packaged into chromosomes and 
contains intron and exon regions in eukariotes. According to the central 
dogma of molecular biology the nucleic acid sequence from the DNA is 
irreversibly transcribed into the messenger RNA, which is then irreversibly 
translated into protein. During the process of splicing the introns are removed, 
and only the exons encode the protein. In brief, DNA makes RNA, and RNA 
makes protein. Hence, it becomes obvious that gene products can be twofold, 
since DNA encodes both RNA and protein. To clarify this ambiguity within the 
above given definition of chemical genetics and the following content of the 
presented thesis, by gene product solely protein is meant. 
A specific feature of chemical genetics lies within the tools used to perturb a 
biological system. These tools are in particular small molecules. Small 
molecules are defined as substances with a molecular weight below 800 Da. 
Some definitions of chemical genetics include also other exogenous ligands. 
These could potentially be antisense RNA, or DNA-targeting reagents. Here, 
we shall focus on protein-binding reagents and small molecules only. This 
specification is essential since the generation and modification of small 
molecule libraries by means of synthetic chemistry is a crucial topic in the field 
of chemical genetics as will be explained further below. 
Small molecules are used to perturb a biological system, but how? The 
question itself already provides one half of the answer, namely that small 
molecule compounds are the elementary parts that perturb the system. This 
appears natural to us, but although plants and their extracts have been used 
for thousands of years to treat diseases, the insight that it is individual 
molecules that reside within the plants that cure the diseases did not come 
until the isolation of morphin from opium by Sertürner in 1804, which marked 
the isolation of the first active compound (Klockgether-Radke, 2002). The  
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second premise, namely that small molecule compounds bind to specific 
protein receptors came 100 years later through the works of Paul Ehrlich and 
Emil Fischer who developed the ideas of a molecular receptor and the  
lock-and-key principle (Stockwell, 2000). This insight, that there is a specific 
interaction between the small molecule and the target protein is key to the 
field of chemical genetics. Today, it is known which forces enable the small 
molecule to interact with the target protein. These are noncovalent 
electromagnetic and electrostatic interactions such as hydrogen bonds and 
salt bridges, and hydrophobic interactions, and steric interactions of the 
partners. There were many crucial steps toward this discovery. On the one 
hand, there was the development of protein sequencing, NMR and 
cristalography methods to study protein structure and the properties of binding 
pockets. On the other hand, there were advances in our understanding of the 
physical forces at the atomic level, as well as progress in organic synthesis 
that allowed chemical modification of the small molecule inhibitors to study 
structure-activity-relationships (SAR). Computational chemistry and molecular 
modeling have equally become valuable modern investigation methods to 
study inhibitor-target interaction. 
Taken together, chemical genetics is the study of gene product functions 
through perturbation with small molecule compounds. Chemical genetics is 
predominantly focused on the perturbation of proteins as gene products. 
Chemical biology and medicinal chemistry also apply small molecules to 
perturb protein functions. Small molecules are used as exogenous ligands to 
perturb protein functions.  
 
1.1.2 Why Chemical Genetics 
 
Conventional gene technology methods have been developed to include very 
sophisticated technologies that allow conditional gene knockouts and 
inducible gene expression. New methods using zink finger nucleases,  
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TALENs, and CRISPR offer elegant ways to modify the genome by 
homologous recombination. These techniques offer convenient ways to study 
genes in a conventional genetic approach. So why do we need chemical 
genetics? 
The chemical genetic approach entails several advantages over conventional 
genetics (Spring, 2005). One very obvious advantage is the simplicity of the 
approach. Gene knockout and knockout mouse technology are laborious and 
tissue consuming. Compared to that, the perturbation by using a small 
molecule inhibitor barely involves more than the step in which the compound 
is added.  
Following the same line, small molecules act instantly and rapidly. Small 
molecules are cell permeable and diffuse directly to their target protein to 
inhibit its function. The inhibition of kinases, for example, by using small 
molecules takes not much longer than 15 min, and the results can be made 
visible by western blotting. Transfections of plasmids can take several hours, 
and viral transductions are usually done over night. After the foreign DNA has 
been introduced into the host it still takes 12 - 48 hours for the introduced 
sequence to be processed. In some cases the cells that need to be analyzed 
do not live long enough, or do not exist long enough in a particular 
developmental state, to allow genetic modifications (Hakkim et al., 2011).  
An important advantage of using small molecules is the fact that the inhibiting 
effect is reversible. If cells are treated with an inhibitor in cell culture all that 
needs to be done is to replace the medium by new medium that is not 
containing the compound, i.e. the small molecule can be washed out. The 
remaining compounds inside the cells will be metabolized or actively 
transported outside the cells. On the other side, if a genetic modification has 
been introduced into the genome it cannot be made reversible. Transient 
transfections have to be analyzed by sequencing to reliably exclude 
integrations into the genome, and inducible or conditional genetic 
perturbations are often accompanied by the problem of "leaking". 
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Chemical genetics allows us to study critical genes where genetic knockouts 
are lethal for the organism or the cell. A genetic knockout might also cause a 
cell type to change, for example by differentiation, so that the cell type of 
interest cannot be studied anymore. Small molecules act instantly and rapidly 
and can be applied to study the gene product of interest at different stages, 
e.g. different developmental stages, to determine the moment at which the 
function of the studied gene product is indispensable. Stat3 knockout mouse 
embryos, for example, die before gastrulation which makes investigations on 
cells derived from Stat3 knockout mice impossible (Takeda et al., 1997). By 
using a small molecule Stat3 inhibitor the role of Stat3 could potentially be 
dissected during embryo development, in embryonic stem cells, as well as 
epiblast stem cells, and even later during differentiation (Schust et al., 2006).  
Chemical genetics also allows the simultaneous study of multiple gene 
products by the application of multiple small molecule inhibitors at the same 
time. Thus, the interaction of several gene products that cause a biological 
effect in a concerted fashion can be studied. Genetic techniques are not as 
convenient for this purpose. Random and multiple integrations, and the 
uncontrolled distribution of the transfected plasmids significantly complicate 
this approach.     
Small molecules can be added at different concentrations, thus, allowing the 
study of dose-dependent effects. The argument of simplicity is here especially 
valid. By adding different amounts of the compound to the biological system 
the function of the gene product can be quantified. This is possible if the small 
molecule acts via noncovalent inhibition which is, however, mostly the case. 
Other relevant arguments in favor of the chemical genetic approach deserve 
to be mentioned such as the possibility to study posttranslational function of 
gene products, safety issues, and practical reasons concerning storage, 
handling and the applicability for high-throughput screening. One argument, 
however, that is of significant and fundamental importance needs to be 
emphasized that is of particular importance for the field of medicinal 
chemistry. As outlined earlier, small molecule inhibitors can be applied to  
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inhibit gene products that cause diseases. The majority of the drugs on the 
market are small molecule inhibitors that have improved life quality and 
increased life expectancy considerably during the course of the 20th century. 
Genetic approaches are obviously very difficult to implement and not 
comparable to the simplicity of orally available drugs for the use at home. The 
originally promising gene therapy is not feasible for the treatment of most 
diseases and has failed to cope with the broad expectations.     
The main disadvantage of chemical genetics as compared to the conventional 
genetic approach is probably the fact that inhibitors are still not available for 
each single gene product. However, there is a global coordination of the 
efforts toward a real chemical genomics through databases like ChemBank 
and PubChem. Another argument is that certain gene products are not 
"druggable" because they are too small and do not have a real binding pocket 
for small molecules. However, although transcription factors have been 
considered as not being target proteins for small molecule inhibition recently 
several successful attempts have been made to target transcription factors 
with small molecules (Koehler, 2010). Finally, although small molecules are 
optimally designed to be specific and potent toward their target protein it is 
sometimes impossible to introduce a perfect selectivity in particular among 
conserved isoforms of protein families so that some small molecules exhibit a 
certain promiscuity among a group of target proteins.   
  
1.1.3 Small Molecule Libraries  
 
The chemical genetic approach can be devided into three main steps: 
generation and expansion of a small molecule library, screening, and target 
identification and validation. That means that certain tools are indispensable 
at each of these three steps. The first such tool is the chemical library of small 
molecule compounds. Small molecule libraries are collections of diverse small 
molecules containing thousands and sometimes millions of compounds.  
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These are stored and tested in automated processes in high-throuput 
screening. Probably the largest and best known libraries are those of big 
pharmaceutical companies that have collected their compounds over 
decades. But compound libraries become increasingly available to academic 
institutions as well through automated screening facilities or smaller 
commercial libraries. Chemical genetics involving high-throughput screening 
is a relatively new field since it was not possible before certain technological 
advances that enabled automated processing, as well as advances in 
synthetic chemistry that made it possible to generate huge compound 
collections in a time and labor efficient manner.  
Probably the biggest step toward chemical diversity was the development of 
solid-phase synthesis of small molecules (Bunin and Ellman, 1992). A starting 
material was attached to an insoluble bead which simplified purification and 
isolation of intermediate products significantly. Earlier chemists focused their 
efforts on the total synthesis of complex natural products. The synthetic 
approach aiming at the generation of one target compound was termed 
target-oriented synthesis (TOS). This allowed chemists to synthesize focused 
libraries by using sequential fragment-coupling reactions.  
The expansion of the applicability of solid-phase synthesis, which was initally 
developed for peptide synthesis only (Merrifield, 1997), to non-peptide 
chemistry marked the beginning of combinatorial chemistry of small molecules 
(Bunin and Ellman, 1992). Combinatorial chemistry includes strategies such 
as parallel synthesis and split-and-pool synthesis and aims at the generation 
of the highest possible number of compounds in as few synthatic steps as 
possible. For the generated compounds the highest possible structural 
diversity and complexity are wanted. This approach with the ultimate goal to 
synthesize an inhibitor for each protein function, i.e. the biologically active 
chemical space, is called diversity-oriented synthesis (DOS) (Schreiber, 
2000). In contrast to TOS which applies retrosynthesis to plan a synthatic 
strategy, i.e. a planning starting from the target compound, DOS sets up the 
synthesis starting from the building blocks. The reactions used are equally  
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important since they should encompass stereochemistry and branching 
pathways to accomplish a fast and efficient synthetic pathway toward 
chemical diversity and complexity (Tan et al., 1998). 
DOS aims at the synthesis of the biologically active chemical space to 
generate an inhibitor for each gene product. A third approach toward this end 
has developed that is mainly concerned with the question how to identify the 
areas in chemical space that are enriched with biologically active compounds 
instead of blindly synthesizing every conceivable substance. It argues that a 
complete synthesis of the entire chemical space is not possible and that there 
is a rational and logical method for the discovery of biologically relevant 
subspace. This approach was termed biology-oriented synthesis (BIOS) 
(Wetzel et al., 2011). In principle, it is a natural product-inspired concept. The 
idea behind it is that natural products have evolved to interact with various 
proteins. First, they specifically interact with the active sites of the enzymes 
that are involved in their biosynthesis. And later, they interact with their 
functional target proteins which they are supposed to inhibit within their 
biological activity. Hence, both natural products as well as the binding pockets 
of proteins are evolutionary tailored to each other. Because of that, within the 
chemical space natural products entail evolutionary designed "privileged 
structures" for biological activity in particular because of their structural 
complexity and widespread presence of stereogenic centers (Wetzel et al., 
2011). These structures have highly conserved scaffolds as it is evident from 
the scaffold trees of the structural classification of natural products (SCONP), 
basically a charter of the chemical space of natural products (Koch et al., 
2005). This bioactive chemical space can be explored through the computer-
based tool Scaffold Hunter (http://scaffoldhunter.sourceforge.net/) (Wetzel et 
al., 2009). The synthesis efforts according to biology-oriented synthesis 
should be oriented around these evolutionary favoured scaffolds. Since, both 
natural products as well as the binding pockets of proteins are evolutionary 
tailored to each other then ligands with similar structures should have an 
affinity to binding pockets of proteins with similar structures. This hypothesis  
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lays the ground for protein structure similarity clustering (PSSC) which is in a 
way the protein analogue of SCONP, a classification of proteins according to 
evolutionary conservation of their binding sites. Both methods of analysis, 
SCONP and PSSC, complement each other in the BIOS approach to select 
relevant scaffolds for the synthesis of focused diversity around the biologically 
active starting point (Wetzel et al., 2011).  
 
1.1.4 Screens 
 
The second tool that is required for chemical genetics are high-throughput 
screening assays. Through the advances in chemical synthesis large libraries 
of small molecules can be synthesized which requires automated and 
miniaturized screening platforms for a time and cost efficient identification of 
active compounds. Therefore, large screening assays are usually performed 
fully automated in 1536-well plates with working volumes of 3 - 10 µl. In 
forward chemical genetics libraries of diverse small molecule inhibitors are 
screened aiming at the discovery of a specific phenotype. This approach is 
analogous to forward genetics where random mutations are introduced into a 
large number of organisms. Then the mutants are screened for the desired 
phenotype of interest, and the mutations of specific genes are analysed that 
caused the phenotype. In forward chemical genetics this involves screening of 
a large library of ligands (mutation equivalents) for a specific phenotype of 
interest followed by target identification to uncover the specific protein that 
caused the phenotype. Target identification will be introduced in the next 
section. 
In contrast to forward genetics where the identification of the mutated gene 
that caused the phenotype of interest is the last step and is not known at the 
onset of the screening assay, in reverse genetics the mutation of a specific 
gene is the starting point. What is not known at the beginning is the 
phenotype that the introduced mutation will cause. In analogy to that, in  
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reverse chemical genetics first the inhibitor of a specific protein of interest has 
to be identified. If the inhibitor is not known yet, an in vitro protein-based 
assay has to be developed to identify the inhibitor of the protein of interst. 
Once the target-based assay has yielded a specific inhibitor of the protein of 
interest a cell-based (in vivo) assay can be performed to analyze the resulting 
phenotype. Depending on the specificity and potency of the discovered 
inhibitor it could be optimized through synthetic modification toward more 
desired features before it is applied in the call based assay.   
An important issue in screening of active compounds is the read-out or 
detection of compound activity that will ultimatelly define the assay quality. 
The field has agreed to use the Z'-factor as a standard method of quality 
assessment of screening assays (Zhang et al., 1999). It is, in brief, a 
statistical coefficient between 0 and 1 that describes the screening window of 
the assay depending on the means and standard deviations of the positive 
and negative controls of the screening assay.  
There are multiple detection methods for in vitro target-based assays. 
Depending on the type of target protein, for example, fluorescence-based 
methods for the determination of enzymatic activity. These include fluorogenic 
enzyme substrates, FRET donor/acceptor pairs, oxygen and pH-sensitive 
probes, and immunoassays.  
Detection methods for cell-based assays, on the other side, include  
high-content imaging, marker gene analysis, and functional assays.  
High-content imaging is based on microscopic imaging to detect phenotypic 
changes. Marker gene or protein analysis includes reporter-gene assays and 
antibody-based cellular immunoassays. In functional assays changes in the 
functional activities of cells are detected, such as growth rate, metabolism, or 
apoptosis.        
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1.1.5 Target Identification and Validation 
 
The third step in the forward chemical genetic approach is target identification 
(target ID) and validation. Target ID is necessary only in forward chemical 
genetics, since reverse chemical genetics starts with the specific perturbation 
of the protein of interest. There have been significant advances in the field of 
target identification during the course of the last two decades. Nevertheless, 
compared to the progress in synthetic chemistry and the technological 
progress leading to fully automated and miniaturized high-throughput 
screening, target ID still remains the most challenging step in chemical 
genetics. This is mainly due to the fact that in contrast to its genetic 
counterpart where advanced whole genome sequencing technology allows 
the rapid and straightforward detection of single mutations that cause an 
observed phenotype, in chemical genetics such a general universally 
applicable protocol for the identification of ligand-protein interactions still does 
not exist. Instead, target identification in chemical genetics employs a variety 
of different approaches toward this end. 
The most common methods currently applied can be divided into proteomics, 
genetics, and bioinformatics (Ziegler et al., 2013). Affinity-based proteomics, 
commonly referred to as "pulldown", is probably the most widely applied 
method. In principal, a pulldown probe is immobilized on an insoluble carrier 
and exposed to a protein cell lysate to bind the target protein. Subsequently, 
the carriers are washed to remove unspecific binding, the attached proteins 
are separated on an SDS-PAGE, digested with trypsin, and the resulting 
peptides are analyzed by mass spectrometry. The pulldown probes are 
generated by synthetically attaching a linker, e.g. alkyl, triethylenglycol, or 
peptide groups, connecting the hit compound to the insoluble bead. Before 
the linker can be attached to the hit compound a structure-activity-relationship 
(SAR) analysis has to be performed to identify the inactive site of the hit 
compound at which the linker can be attached without disturbing the 
compound's activity. An important point in protein pulldown are control  
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experiments. Since pulldowns can result in a lot of unspecific binding stringent 
washing steps are essential as well as the inclusion of control experiments 
using only the linker attached to the carrier resin and a slightly modified hit 
compound that exhibits a significantly reduced activity. The final analysis by 
mass spectrometry should result in a list of candidate proteins for further 
confirmation. Quantitative proteomics by isotope labeling, such as SILAC, are 
very powerful methods to quantify the affinity of the attached proteins to the 
pulldown probe (Ong et al., 2002). 
Another protein-based method for target identification are in vitro profiling 
experiments against a target subclass such as kinases, phosphatases, or  
G protein-coupled receptors (GPCR). Profiling assays against various target 
classes are commercially offered by different companies. This step is usually 
taken once there are hints that indicate a certain target class. An additional 
advantage of profilings is the simultaneous target validation, i.e. assessment 
of the specificity of the profiled compound to a particular target protein. 
Microarray technology is a very efficient tool among the genetic methods for 
target identification. It allows an examination of the global changes in gene 
transcription patterns that are caused by a small molecule compound. 
Through the use of proper control inhibitors micro array analyses can help to 
identify the perturbed signaling pathways by subjecting the differentially 
expressed genes to gene ontology (GO) analysis. If the specific modulation of 
target genes of a particular signaling pathway is observed known components 
of that signaling cascade can be investigated by biochemical methods to 
identify the specific protein target. A disadvantage of micro array-based target 
identification methods is the fact that only changes at the RNA level can be 
observed. Hence, one can only indirectly deduce the protein target  from the 
perturbed signaling pathways and the affected target genes which is mostly 
not straightforward. Proper control compounds, statistically relevant technical 
and biological repetitions, and treatments for only very short time periods to 
detect instant effects are indispensable to obtain reliable data. Once a  
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potential target protein is identified it needs to be validated, i.e. scientific 
evidence needs to be provided to confirm that the candidate protein  
is undoubtedly causing the phenotype. Multiple methods must be applied 
simultaneously toward this end. The affinity of the hit compound toward the 
candidate protein must be verified in an in vitro assay, and a dose response 
curve should be generated. Selectivity of the hit compound is equally 
important and can be assessed by profiling against members of various 
protein families and different isoforms of the same protein family. Global 
transcriptome analyses are also suitable to analyse the caused effects within 
the cellular environment. Structurally diverse inhibitors of the same target 
protein could then be applied to reproduce the phenotype, or the affected 
signalling pathway could be modified upstream or downstream using suitable 
inhibitors. The gold standard, however, to confirm the protein target within the 
cell environment is a gene knockdown of the target protein that results in the 
same phenotype. If possible, the mechanism of action of the hit compound 
should be validated in a suitable in vivo assay, for example using a transgenic 
model organism. Eventually, it depends on the given project which 
experiments are most suitable to substantiate the data in support of a 
candidate protein.   
 
 
1.2 Pluripotent Stem Cells 
 
1.2.1 Mouse Embryonic Stem Cells (mESC) 
 
Pluripotent stem cells share two common features that distinguish them from 
other cell types: self-renewal and pluripotency. Self-renewal is defined as the 
cells' ability to maintain their pluripotent cell state indefinitely. It is a sort of 
immortality that allows the cells to be expanded in cell culture for an extended 
period without losing their pluripotency. Pluripotency, on the other hand, is the 
cells' capacity to give rise to all somatic cell types of an adult organism. The  
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derivation of somatic cells from pluripotent stem cells is called differentiation. 
Cells with these two features do not exist in the adult human body. Solely, 
cells with a limited differentiation capacity capable of self-renewal are found in 
the adult body (Wagers and Weissman, 2004). These cells are called adult 
stem cells, or multipotent stem cells to emphasize their limited differentiation 
potential. Examples include haematopoietic or mesenchymal stem cells 
residing in the bone marrow. During development pluripotent stem cells exist 
solely during a narrow time frame and in the early embryo.  
Embryonic stem cells were isolated from the mouse embryo and maintained 
in cell culture in 1981 (Evans and Kaufman, 1981; Martin, 1981). Briefly, after 
the fertilization of the zygote in the oviduct up to the 8-cell stage the embryo 
remains totipotent, i.e. capable of generating extraembryonic tissue, the 
placenta, as well as all somatic cells of the embryo proper. Subsequently, the 
blastocyst is formed containing the trophoectoderm and the inner cell mass 
(ICM) in which the embryonic stem cells reside that will eventually form the 
embryo. It is at this stage of development that embryonic stem cells are 
derived. For mouse this is in most cases at E3.5 of the preimplantation 
embryo, but could be also half a day earlier, or later.    
Two types of tests are widely applied to assess the pluripotency of cells: the 
teratoma formation assay and the chimera assay. Pluripotent cells that are 
injected into the flanks of immunodeficient mice form teratomas that contain 
somatic cells of all three germ layers that result from the differentiation of the 
injected cells. Histological analysis is used to confirm the proper development 
into all three germ layers. On the other hand, if pluripotent cells are injected 
into the blastocysts of host embryos, and the blastocysts are subsequently 
transferred into pseudo-pregnant foster mice the injected pluripotent cells will 
contribute to the development of all somatic cell types of the developing 
embryo (Bradley et al., 1984). The resulting mice will be derived from two 
types of cells, those that were injected and those from the host embryo. 
Hence, the derived mice will be chimeric. Chimerism can be made obvious 
from the firm color of the derived mice if the injected cells and the host  
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embryos are selected properly. The gold standard test for pluripotency is 
tetraploid complementation in which all cells in the ICM of the host embryo are 
replaced by the cells to be tested so that the resulting embryo is completely 
derived from the injected cells. 
In cell culture mouse embryonic stem cells grow in small, oval, dome-shaped 
colonies. They are usually grown on a feeder cell layer of mouse embryonic 
fibroblasts (MEF) or feeder-free, e.g. on gelatin-coated cell culture plates. 
They are passaged as single cells using trypsin and exhibit high clonogenicity. 
Mouse embryonic stem cells have both active X chromosomes in female cells. 
Their pluripotency is maintained through a core regulatory network of the key 
transcription factors Oct4, Sox2, Nanog, Klf2, and Klf4. This core regulatory 
network is extrinsically controlled through the LIF/STAT3 and BMP4 pathways 
(Niwa et al., 2009; Ying et al., 2003). In contrast to that, it has been found that 
stimulation of ERK signaling primes mESC for differentiation (Burdon et al., 
1999; Kunath et al., 2007; Stavridis et al., 2007). Examples of specific gene 
markers that characterize mESC include Rex1, Esrrb, Dppa3, Dppa5, Klf2, 
and Gbx2, and prominant cell-surface markers are SSEA1 and alkaline 
phosphatase.    
 
1.2.2 Human Embryonic Stem Cells (hESC) 
 
It was not until 1998 that human embryonic stem cells were derived and 
maintained in cell culture (Thomson et al., 1998). Their potential to give rise to 
all somatic cell types principally opened doors toward cell replacement 
therapies of dysfunctional or damaged tissues (Kehat et al., 2001; Zhang et 
al., 2001). Especially the arrival of human induced pluripotent stem cells 
(iPSC), which are human pluripotent cells that are indistinguishable from 
embryonic stem cells that are derived, however, from somatic cells through 
nuclear reprogramming, caused a tsunami of scientific activity in this field 
(Takahashi et al., 2007).  
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Like mESC, hESC are derived from the ICM of the preimplantation embryo. 
The human embryo, however, reaches the blastocyst stage at E4 - 5. Human 
ESC are cultured on MEF feeder cells or matrigel-coated cell culture plates. 
However, although hESC, like mESC, are derived at the blastocyst stage from 
the ICM of preimplantation embryos they have certain features that distinguish 
them from mESC. Distinctions are apparent already at the morphology level. 
While mESC grow in small, oval, dome-shaped colonies, hESC form large, 
round, flat, colonies. The maintenance of mESC pluripotency works through 
LIF/STAT3 and BMP4 signaling (Niwa et al., 2009; Ying et al., 2003), whereas 
hESC are maintained through Activin A and FGF2 (Greber et al., 2011; 
Greber et al., 2010; Xu et al., 2008). In contrast to that, ERK stimulation 
primes mESC for differentiation (Burdon et al., 1999; Kunath et al., 2007; 
Stavridis et al., 2007). HESC exhibit low clonogenicity when passaged as 
single cells. Usually a ROCK inhibitor is applied to inhibit apoptosis if hESC 
are dissociated into single cells (Watanabe et al., 2007). HESC are either 
passaged mechanically as small clumps, or by using collagenase or accutase. 
On the gene level hESC share the pluripotency core regulatory network 
consisting of OCT4, NANOG, and SOX2, and also express the mESC marker 
genes REX1, ESRRB, DPPA3, DPPA5, KLF2, and GBX2. While mESC 
express the cell-surface marker SSEA1, but not the cell-surface markers 
SSEA3, SSEA4, and Tra-1-60, hESC do not express SSEA1, but SSEA3, 
SSEA4, and Tra-1-60 (Pera and Tam, 2010). HESC are, like mESC, positive 
for alkaline phosphatase. As mentioned earlier the gold standard experiment 
for the verification of pluripotency is tetraploid complementation. Chimera 
experiments are obviously not possible with hESC. HESC do, however, give 
rise to teratomas with cells of all three germ layers when injected into 
immunodeficient mice.  
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1.2.3 Epiblast Stem Cells (EpiSC) 
 
Epiblast stem cells represent another mouse pluripotent cell type. They were 
first isolated in 2007 (Brons et al., 2007; Tesar et al., 2007). However, in 
contrast to mESC and hESC, which are derived from the ICM of 
preimplantation embryos, EpiSC are derived between E5.5 - 7.5 from 
postimplantation mouse embryos. Since EpiSC can be maintained stably in 
prolonged cell culture they provide a convenient and relevant system for the 
study of developmental events in the pregastrulation embryo through 
investigations of the changes in cell fate between mESC and EpiSC.  
EpiSC are pluripotent stem cells capable of indefinite self-renewal and 
differentiation into all somatic cell types. They readily form teratomas. The 
pluripotency core regulatory network consists of Oct4, Nanog, and Sox2, as in 
mouse and human ESC. However, there are significant differences between 
mESC and EpiSC that clearly distinguish the two cell types. While mESC 
grow in small, oval, dome-shaped colonies EpiSC grow in large, round, and 
flat colonies very similar to hESC colonies. They are passaged using 
accutase, collagenase, or mechanically as small clumps since they do not 
tolerate well single cell dissociation like hESC. Furthermore, like hESC they 
are maintained pluripotent by Activin A and FGF2, in contrast to LIF and 
BMP4 in mESC (Greber et al., 2010). On a genetic level they do not express 
the ICM marker genes Rex1, Esrrb, Dppa3, Dppa5, Klf2, and Gbx2, but some 
early differentiation markers like Fgf5, Fgf8, and T brachyury (Pera and Tam, 
2010). EpiSC do express the cell-surface marker SSEA1, however not 
SSEA3, SSEA4, and alkaline phosphatase. Also, when mESC develop into 
EpiSC one X chromosome undergoes random inactivation in female cells. 
The most important difference between mESC and EpiSC, however, is the 
fact that EpiSC are not chimera competent in contrast to mESC (Bradley et 
al., 1984; Guo et al., 2009; Tesar et al., 2007). EpiSC only form teratomas. 
In light of the above mentioned similarities EpiSC, rather than mESC, appear 
to be the counterpart of hESC. However, there are also crucial differences  
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between the two cell types. In contrast to EpiSC hESC do express all the ICM 
markers such as REX1, ESRRB, DPPA3, DPPA5, KLF2, and GBX2 similar to 
mESC. Furthermore, EpiSC do not express the cell-surface markers SSEA3, 
SSEA4, and alkaline phosphatase unlike hESC (Pera and Tam, 2010). On 
grounds of the described discrepancies the different pluripotent states 
continue to be studied intensively.  
 
1.2.4 Naïve and Primed Pluripotency 
 
Two distinct pluripotent states have been described in the mouse system: one 
is represented by mESC and the other by EpiSC. HESC appear to share 
more similarities with mouse EpiSC than with mESC despite some  
non-neglectable differences. mESC are distinct from EpiSC on several levels 
including derivation, morphology, clonogenicity, signaling, marker expression, 
and epigenetic markup. Most importantly, however, while both mESC and 
EpiSC readily form teratomas only mESC can contribute to chimera 
development while EpiSC can not (Bradley et al., 1984; Guo et al., 2009; 
Tesar et al., 2007). This is consistent with the earlier finding that epiblast cells 
cannot contribute to chimeras when injected into the blastocyst (Rossant, 
2008). This developmental restriction in EpiSC together with the presence of 
early lineage markers has come to be called primed pluripotency, in the sense 
of primed for differentiation (Nichols and Smith, 2009). In contrast, the cells of 
the ICM with fully unrestricted developmental capacity have been said to 
represent the ground state of pluripotency, or naïve pluripotency. 
The two distinct states of pluripotency represented by mESC and EpiSC have 
been intensively investigated since by profiting from the fact that both cell 
types can be stably maintained in cell culture. Hence, through interconversion 
of the two cell types, for example, the distinct features could be explored. 
EpiSC could be derived from mESC through differentiation by adapting mESC 
to the culture conditions of EpiSC, i.e. Activin A, FGF2 and withdrawal of LIF 
(Guo et al., 2009). The conversion of EpiSC to mESC through ectopic  
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expression of ICM-specific transcription factors has equally been reported 
(Festuccia et al., 2012; Gillich et al., 2012; Guo and Smith, 2010; Guo et al., 
2009; Hall et al., 2009; Silva et al., 2009; Tai and Ying, 2013). Other studies 
have reported that transgenic expression is not required, and that EpiSC 
could be converted into ESC by a change in the culture conditions only (Bao 
et al., 2009; Chou et al., 2008; Greber et al., 2010; Hanna et al., 2009; Ware 
et al., 2009). Among these methods the most widely established protocol for 
the conversion is based on the simultaneous inhibition of GSK3# and MEK in 
the presence of LIF, which came to be known as 2i/LIF (Greber et al., 2010). 
This is based on the previous finding that inhibition of GSK3# and MEK with 
small molecule inhibitors can capture and maintain naïve pluripotency 
independent of other factors (Ying et al., 2008).  
The similarity between hESC and EpiSC has prompted researchers to 
investigate whether a mESC-like hESC state could exist. Different attempts 
using ectopic expression and extrinsic factors have been made to generate 
naïve hESC (Buecker et al., 2010; Gafni et al., 2013; Hanna et al., 2010; 
Ware et al., 2009). However, to this date no transgene-free stable cells have 
been generated. Furthermore, it is still widely disputed whether a mESC-like 
equivalent naturally exists in humans. In rodents a natural developmental 
arrest at the late preimplantation stage occurs that prevents the implantation 
of the embryo into the uterus called diapause. At this developmental stage the 
self-renewal of the naïve epiblast from which mESC are derived is facilitated 
in these species. Diapause does not occur in humans.  
 
1.2.5 Early-Stage and Recalcitrant Late-Stage EpiSC 
 
It has previously been shown that EpiSC display heterogeneity within a 
population (Han et al., 2010; Tsakiridis et al., 2014) and between different cell 
lines (Bernemann et al., 2011). The heterogenous cell populations exhibit 
distinct functional features such as the propensity to convert to an ESC-like  
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state under culture conditions. Part of this heterogeneity is probably due to the 
broad developmental window of derivation. In this regard, it has been 
suggested that early-stage EpiSC are susceptible to cellular reprogramming 
towards an ESC-like state, whereas late-stage EpiSC are recalcitrant to this 
process (Han et al., 2010; Hayashi and Surani, 2009). However, the majority 
of EpiSC display functional features of late-stage postimplantation epiblast 
development. The very small subpopulation which respresents early-stage 
EpiSC capable of undergoing reversion to an ESC-like state under 2i/LIF is 
even chimera competent when injected into the ICM (Han et al., 2010). Given 
their chimera competence which is the hallmark feature of naïve pluripotency 
their ESC conversion by 2i/LIF represents merely a switch in the signaling 
pathways that maintain their pluripotency network from TGF#/Activin A and 
FGF2 to LIF/STAT3 and BMP4. The vast majority of EpiSC fail to respond to 
2i/LIF-induced ESC conversion indicating their inertness toward chemical 
modulation of the ERK and WNT pathway in this process. To our knowledge 
until now nobody has explored the mechanistic accounts for the recalcitrance 
of late-stage EpiSC toward ESC-conversion by chemical means only.   
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2. Aims and Objectives 
 
 
It has previously been reported that mouse EpiSC lines comprise 
heterogenous populations, which can be functionally equivalent to cells of 
either the early or the late stages of postimplantation development. So far, 
late-stage EpiSC which represent the vast majority of EpiSC were not 
susceptible to chemical reprogramming to naïve pluripotency as represented 
by mESC.  
At the onset of the presented research project the goal of the thesis was to 
elucidate the molecular mechanism governing the reversion from primed to 
naïve pluripotency. Toward this end, three different questions needed to be 
answered: Can recalcitrant late-stage EpiSC be reverted to a naïve ESC-like 
state by chemical means alone, i.e. without genetically invasive methods? If 
so, which extrinsic factors can accomplish naïve conversion of late-stage 
EpiSC? What is the mechanism-of-action of the extrinsic factor? 
It was hypothesized that it may be possible to revert late-stage EpiSC by 
using appropriate small molecule inhibitors that would modify certain signaling 
pathways in a way that would result in the necessary switch in the gene 
expression pattern that will eventually enforce naïve conversion.    
In order to identify a small molecule compound capable of converting  
late-stage EpiSC a forward chemical genetic approach was followed. Toward 
this end, first a small molecule screening assay was developed. In order to 
ensure cell penetration and bioactivity of the used substances and to facilitate 
potential subsequent target validation I planned to screen the LOPAC library 
of known pharmacologically active compounds. The read-out should be based 
on fluorescent reporter gene expression. The OCT4-GFP EpiSC-GOF18 line 
was used for this purpose. An automated high-content imager could be used 
for the detection of converted OCT4-GFP positive cells. 
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The potential hit compound should first be validated on various late-stage 
EpiSC to confirm its activity. The putative converted cells should be 
characterized to confirm their naïve pluripotency including teratoma and 
chimera assays. As a way to elucidate the mechanism-of-action the direct 
protein target of the hit compound should be identified using various methods 
for target identification including protein pulldown. Structure-activity-
relationship analyses were to be performed toward structure optimization and 
possible pulldown probe generation. Finally, microarray analyses, biochemical 
assays, and gene knockdown experiments should be applied to investigate 
perturbed pathways and crucially involved genes as part of the elucidation of 
the mechanism-of-action of the hit compound.    
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3. Experimental Part 
 
 
3.1 Materials 
 
3.1.1 Cell Culture  
 
PBS w/o Ca/Mg (PAA)  
DMEM high glucose (PAA) 
Knockout - DMEM (Invitrogen) 
DMEM/F12 (Invitrogen) 
Neurobasal (Invitrogen) 
FCS Gold (PAA) 
Knockout - Serum Replacement (Invitrogen) 
L-Glutamine with Pen/Strep (PAA) 
Non-essential amino acids (PAA) 
2-Mercaptoethanol (Invitrogen) 
0.25% Trypsin (Invitrogen) 
Accutase (PAA) 
N2-Supplement (Invitrogen) 
B27-Supplement (Invitrogen) 
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3.1.2 Growth Factors and Small Molecule Inhibitors 
 
Human basic fibroblast growth factor (bFGF) (Peprotech) 
Human leukemia inhibitory factor (LIF) (own production) 
Human/murine/rat Activin A (Peprotech) 
Human bone morphogenetic protein 4 (BMP4) (Peprotech) 
CHIR99021 (CH) (Tocris) 
PD0325901 (PD) (Tocris) 
SB431542 (SB) (Tocris) 
XAV939 (Tocris) 
IWR-1 (Sigma) 
Amiloride (Sigma) 
Triamterene (Sigma) 
D4476 (Tocris) 
AS605240 (Alexis) 
LY294002 (Sigma) 
TG100-115 (in house synthesis) 
Jak Inhibitor 1 (EMD Millipore) 
Y-27632 (Tocris) 
Hoechst 33258 (Sigma) 
DAPI (Invitrogen) 
Sodium butyrate (Sigma) 
AU49 (in house synthesis)  
AU52 (in house synthesis) 
AU58 (in house synthesis) 
LOPAC1280 library (Sigma)  
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3.1.3 Cell Culture Media 
 
• ESC medium 
Knockout-DMEM  
20% Knockout - Serum Replacement   
1x L-Glutamine with Pen/Strep 
1x Non-essential amino acids  
100 µM 2-Mercaptoethanol  
2000 units/mL LIF  
 
• ESC medium (N2B27)  
50% DMEM/F12 
50% Neurobasal 
1x N2 Supplement 
1x B27 Supplement 
1x L-Glutamine with Pen/Strep (PAA)  
1x Non-essential amino acids  
100 µM 2-Mercaptoethanol  
10 ng/mL LIF 
10 ng/mL BMP4 
 
• EpiSC medium (MEF-conditioned; CM) 
Knockout-DMEM  
20% Knockout - Serum Replacement  (KOSR) 
1x L-Glutamine with Pen/Strep 
1x Non-essential amino acids  
100 µM 2-Mercaptoethanol  
5 ng/mL bFGF (before and after conditioning over MEFs) 
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• EpiSC medium (N2B27 medium) 
50% DMEM/F12 
50% Neurobasal 
1x N2 Supplement 
1x B27 Supplement 
1x L-Glutamine with Pen/Strep (PAA) 
1x Non-essential amino acids  
100 µM 2-Mercaptoethanol  
20 ng/mL Activin A 
12 ng/mL bFGF 
 
• MEF medium 
DMEM high glucose  
10% FCS Gold 
1x L-Glutamine with Pen/Strep 
 
• HEK293 medium 
DMEM high glucose  
10% FCS Gold 
 
• Cryopreservation medium 
45% culture medium of cell type to be cryopreserved 
45% FCS or Knockout - Serum Replacement (same as in culture 
medium) 
10% DMSO 
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3.1.4 Cell Lines 
 
• EpiSC-GOF18 
E3 
(C57BL/6 X DBA/2) X 129/Sv  
derived at E5.5 
OCT4-GFP under control of 18kb (DE and PE) Oct4 promoter 
(Bernemann et al., 2011; Greber et al., 2010; Yeom et al., 1996) 
 
• EpiSC-OG2 
(CBA/CaJ X C57BL/6J)F2X129 X C57BL/6J 
derived at E5.5 
OCT4-GFP under control of $PE Oct4 promoter 
(Bernemann et al., 2011; Greber et al., 2010; Yeom et al., 1996) 
 
• EpiSC-T9 
129S2/SvHsd 
derived at E5.5 
(Tesar et al., 2007) 
 
• EpiSC-C1a1 
B6XCBA F1 
derived at E5.5 
(Brons et al., 2007) 
 
• ESC-OG2 
C57BL/6J 
derived at E3.5 
OCT4-GFP under control of $PE Oct4 promoter 
(Yeom et al., 1996) 
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• Bcateninfl/fl  ESC  
(provided by Dr Ian Chambers and Dr Rodrigo Osorno) 
Rosa26-CreERT2  
C57/B6 
derived at E3.5 
Upon treatment with 4-OH cells become Bcatenin-/-,  and GFP 
expression is acquired constitutively.  
(Brault et al., 2001; Tsakiridis et al., 2014) 
 
• Stat3-/- ESC 
(provided by Dr Ian Chambers and Dr Rodrigo Osorno) 
MF1 
derived at E3.5 
(Ying et al., 2008) 
 
• TNGETC1 ESC 
(provided by Dr Ian Chambers and Dr Rodrigo Osorno) 
Homologous recombination was used to insert eGFP at the Nanog 
AUG codon in E14Tg2a ES cell (Chambers et al., 2007). 
Subsequently, TdtTomato was inserted just before the 3’ UTR of the 
Esrrb (Festuccia et al., unpublished). 
(Chambers et al., 2007) 
 
• Mouse embryonic fibroblasts (MEF) 
CF1 
derived at E12.5 
 
• HEK293T cells 
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3.1.5 Antibodies  
 
For immunocytochemistry: 
 
• Nanog 
ab70482 
1:500 dilution 
(Abcam) 
 
• Nanog 
14-5761-80 
1:500 dilution 
(eBioscience)  
 
• Sox2 
sc17320 
1:500 dilution 
(Santa Cruz) 
 
• Sox2 
sc-17320 
1:500 dilution 
(Santa Cruz) 
 
• Stella/Dppa3 
ab19878 
1:300 dilution 
(Abcam) 
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• Esrrb 
PP-H6705-00 
1:500 dilution 
(Persaeus Proteomics) 
 
• Klf4 
AF 3158 
1:500 dilution 
(R&D Systems)  
 
• Oct4 
sc-5279 
1:500 dilution 
(Santa Cruz)  
 
 
For Western blot analysis: 
 
• #-catenin  
C19220-050 
1:500 dilution 
(BD Biosciences) 
 
• p-S33/S37/T41-#-catenin  
#9561 
1:1000 dilution 
(Cell Signaling)  
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• Smad2/3  
#3102 
1:1000 dilution 
(Cell Signaling)  
 
• p-S465/467-Smad2  
#3101 
1:1000 dilution 
(Cell Signaling)  
 
• ERK  
#9102 
1:2000 dilution 
(Cell Signaling)  
 
• p-ERK  
#4370 
1:2000 dilution 
(Cell Signaling)  
 
• Stat3  
sc482 
1:1000 dilution 
(Santa Cruz) 
 
• p-Stat3 
sc8059 
1:1000 dilution 
(Santa Cruz) 
 
3.     Experimental Part 
_____________________________________________________________________ 
! &%!
 
 
• Alpha-tubulin 
T6199 
1:10000 dilution 
(Sigma) 
 
 
For FACS analysis: 
 
• CD31/Pecam1  
551262 
1:100 dilution 
(BD Biosciences) 
 
 
3.1.6 qRT-PCR Primers  
 
All qRT-PCR primers were synthesized by Metabion International AG, 
Martinsried, Germany. 
 
• Axin2 
F: TAGGCGGAATGAAGATGGAC 
R: CTGGTCACCCAACAAGGAGT 
 
• Beta-actin 
F: ACTGCCGCATCCTCTTCCTC 
R: CCGCTCGTTGCCAATAGTGA 
 
• Cdx1 
F: GGGGTCACTGTGGACAAACT 
R: GGCCTAGGACACAAGAGCTG 
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• Csnk1delta 
F: ATGCCATTTGGGTTTGTCAT 
R: CACCACACCTTTCTGGAGGT 
 
• Csnk1epsilon 
F: GCTCGAATGTGTGAAGACGA 
R: CGTCTTGAGGCTGAACTTCC 
 
• Dppa4 
F: CGGGCGTCATAACCAGTTCA 
R: GACATGCATGCGGAGGCTAC 
 
• Dppa5 
F: TGTGTCTCCGACCTGGATGC 
R: CACATCAGAATGCGCAGCAG 
 
• Esrrb 
F: AGGCTCTCATTTGGGCCTAGC 
R: ATCCTTGCCTGCCACCTGTT 
 
• Fgf5 
F: CCTTGCGACCCAGGAGCTTA 
R: CCGTCTGTGGTTTCTGTTGAGG 
 
• Fgf8 
F: TCGCGAAGCTCATTGTGGA 
R: GCCGTTGCTCTTGGCAATTAG 
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• Gapdh 
F: CCAATGTGTCCGTCGTGGAT 
R: TGCCTGCTTCACCACCTTCT 
 
• Klf2 
F: AGGCCTGTGGGTTCGCTATAAA 
R: GGCAAATTATGGCTCAAAGTAGCAG 
 
• Klf4 
F: TGTGTCGGAGGAAGAGGAAGC 
R: ACGACTCACCAAGCACCATCA 
 
• Nanog 
F: GAACGGCCAGCCTTGGAAT 
R: GCAACTGTACGTAAGGCTGCAGAA 
 
• Oct4 
F: TGTTCCCGTCACTGCTCTGG 
R: TTGCCTTGGCTCACAGCATC 
 
• Rex1 
F: GGCTGCGAGAAGAGCTTTATTCA 
R: AGCATTTCTTCCCGGCCTTT 
 
• Sox1 
F: GGCCGAGTGGAAGGTCATGT 
R: TCCGGGTGTTCCTTCATGTG 
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• Sox2 
F: TTCGAGGAAAGGGTTCTTGCTG 
R: TCCTTCCTTGTTTGTAACGGTCCT 
 
• Stella 
F: GCCGCACAGCAGATGTGAA 
R: AAATCTGGATCGTTGTGCATCCT 
 
• T brachyury 
F: TTGAACTTTCCTCCATGTGCTGA 
R: TCCCAAGAGCCTGCCACTTT 
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3.1.7 Primers for Bisulfite Sequencing 
 
All primers for bisulfite sequencing were synthesized by Metabion 
International AG, Martinsried, Germany. 
 
• OCT4-GFP 
F1: GTTTTTTTATTTATTTAGGGGG 
R1: AAATAAACTTCAAAATCAACTTACC 
F2: GGGGTTAGAGGTTAAGGTTAGAGG 
R2: ACCAAAATAAACACCACCCC 
 
• Oct4 endo 
F1: TTTGTTTTTTTATTTATTTAGGGGG 
R1: ATCCCCAATACCTCTAAACCTAATC 
F2: GGGTTAGAGGTTAAGGTTAGAGGG 
R2: CCCCCACCTAATAAAAATAAAAAAA 
 
• Esrrb 
F1: TGTAAAAGATAGGGTTTTTGATTTGA 
R1: AAAACAATACCAAAACCACCACTAA  
 
• Rex1 
F1: TATATTAATGTTGGAAAAAGTTTAGGTAAT 
R1: AACTCCTTAAACCCCTCCCTTTTTAAATAA 
F2: GTTTAGGTAATTAGTGTATTTTGTAG 
R2: TAAACCCCTCCCTTTTTAAATAAAC 
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• Dppa3/Stella 
F1: ATTTTGTGATTAGGGTTGGTTTAGAA 
R1: CCAAAACATCCTCTTCATCTTTCTTCT 
F2: TTTTTGGAATTGGTTGGGATTG 
R2: CTTCTAAAAAATTTCAAAATCCTTCATT  
 
• Dppa5 
F1: GGTTTGTTTTAGTTTTTTTAGGGGTATA 
R1: CCACAACTCCAAATTCAAAAAAT 
F2: TTTAGTTTTTTTAGGGGTATAGTTTG 
R2: CACAACTCCAAATTCAAAAAATTTTA 
 
• Vasa 
F1: ATAATGGAATTGATGAGTTTTTGGA 
R1: AAAACAACAAATAACATCAAAC 
F2: GGTTTTAATAAAGGTGGAGAA 
R2: AAAACAACAAATAACATCAAAC 
 
• Pecam1 
F1: TTTTTAGTTTGGAGGTTTGTATTTG 
R1: CCCAAACCTCATTATTCTTAATTTC 
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3.1.8  Other Materials and Kits 
 
• RNeasy Micro/Mini Kit for total RNA extraction  (Qiagen) 
• ZR plasmid miniprep kit (Zymo Research) 
• NucleoBond Xtra plasmid midi/maxiprep kit (Macherey-Nagel) 
• DNAse I (Macherey-Nagel) 
• M-MLV Reverse Transcriptase (USB) 
• Oligo-dT16 primers (Metabion) 
• dNTPs (USB) 
• 5x RT buffer (USB) 
• SYBR green PCR master mix (Biorad) 
• mouseRef-8 V2 expression BeadChips (Illumina) 
• linear TotalPrep RNA amplification kit (Ambion) 
• Dual-Glo luciferase assay (Promega) 
• Super TOP/FOP plasmids (Addgene) 
• Lipofectamin 2000 (Invitrogen) 
• FuGENE 6 (Promega) 
• Opti-MEM medium (Invitrogen) 
• DNeasy Blood & Tissue kit (Qiagen)  
• QIAquick gel extraction kit (Qiagen) 
• EpiTect bisulfite kit (Qiagen) 
• DNA proofreading polymerase (NEB) 
• TOPO cloning kit for sequencing  (Invitrogen) 
• KinaseProfiler / IC50Profiler Services (Merck/Millipore; now Eurofins) 
• shRNA plasmids (Sigma) 
• Fast Red chromogen (Sigma) 
• Naphthol phosphate solution (Sigma) 
• Mounting medium (Invitrogen) 
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3.2 Methods 
 
3.2.1 Derivation and Culture of MEF Feeder Cells 
 
It is important to ensure that sterilized surgery instruments are used and that 
the surgical dissection is performed under a sterile hood. For the generation 
of MEF feeder cells E12.5 embryos from CF1 mice were dissected out from 
the uterus and washed in a 10cm cell culture dish containing prewarmed PBS. 
The washed embryos were then transfered to a new 10cm dish with 
prewarmed MEF medium and the heads and livers were of each embryo was 
removed. Then the remaining embryo tissue of three embryos was cut into 
small pieces in a microtube using scissors. 500 µl of fresh MEF medium was 
added to the minced embryo material and the whole content was transferred 
onto a 100 µm cell strainer in a 6-well plate. The material was gently passed 
through the mesh with the syringe plunger, while making sure that the filter 
membrane was immersed in media. The filtrate from the 6-well plate was 
transferred to a 50 ml Falcon tube filled with MEF media and the cell 
suspension was homogenized by trituration. Then the entire cell suspension 
was transferred to a 15cm cell culture plate and was incubated at 37 °C. The 
medium was changed after 6-7 hrs to remove floating cells and debris. The 
confluent cell monolayers were split 1:4 after 48 hrs and the susequent 
confluent cultures were frozen until they were used. The derived MEFs were 
expanded by passaging up to six times using trypsin before they were used 
as feeder cells for ESC culture.  
 
3.2.2 Generation of MEF-Conditioned Medium  
 
For feeder free culture of EpiSC on FCS-coated dishes EpiSC medium based 
on 20% KOSR in KO-DMEM was conditioned over CF1 MEFs. For this 
purpose CF1 MEFs were seeded out in gelatin-coated 15cm plates at a 
density of 50,000 cells/cm2. The next day the MEFs were %-irradiated by  
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exposure to 4000 rads from a %-radiation source for mitotic inactivation. After 
removing the MEF medium and washing with 1x PBS (w/o Ca2+ and Mg2+) 
80 ml of unconditioned EpiSC medium containing 5 ng/ml bFGF were added 
to the 15cm plate and the cells were kept for 24 hrs at 37 °C. Subsequently, 
the conditioned medium was collected from the culture dishes and new 
unconditioned medium was added conditioning. This process was repeated 
for six consecutive days. After that the collected conditioned madium was 
pooled together and filtered through a 0.22 µm sterile filter, aliquoted into 50 
ml Falcon tubes, and stored at -20 °C. Prior to use bFGF was additionally 
added directly to the culture dish at a concentration of 5 ng/ml.     
 
3.2.3 Culture of EpiSC 
 
EpiSC were routinely cultured in MEF-conditioned medium on feeder-free 
dishes that had been precoated with fetal calf serum (FCS) for 15 min at RT. 
After precoating the FCS was aspirated and the culture dishes were washed 
with plenty of PBS. EpiSC were passaged as soon as individual colonies were 
about to grow into each other initiating differentiation. Prior to their 
dissociation using accutase the differentiated areas were removed 
mechanically with an injection needle under a stereo microscope in a laminar 
flow hood. The dissociated colonies were seeded as single cells at 
approximately 15,000 cells per 6cm dish if not indicated otherwise, and new 
bFGF was added directly into the cell culture dish. The cells were kept at  
37 °C and the cell culture medium was replaced daily.  
 
3.2.4 Culture of ESC 
 
ESC were routinely cultured either on MEF feeder cells, or on feeder-free cell 
culture dishes that were precoated with 0.1% gelatin in PBS for at least  
1 hr at RT. MEF feeder cells were seeded at a density of 50000 cells/cm2 on 
0.1% gelatin-coated dishes and were cultured overnight at 37 °C before they  
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were mitotically inactivated by %-radiation the next day. ESC were passaged 
at 90% confluency using trypsin, and the single cells were seeded at 150,000 
cells per 6cm dish if not otherwise indicated. If the ESC were cultured on MEF 
feeder cells, before they were reseeded on a new MEF feeder layer they were 
cultured for 2 x 1 hr on a gelatin-coated dish to remove the previous MEF 
cells by faster attachment to the gelatin-coated surface. The cells were kept at 
37 °C and the cell culture medium was replaced every other day.  
 
3.2.5 Freezing and Thawing of Cells 
 
Cells were dissiociated to single cells using the appropriate dissociation 
enzyme. Prior to dissociation differentiated cell colonies were mechanically 
removed with an injection needle or a pipette under a stereo microscope in a 
laminar flow hood. Usually the EpiSC or ESC cells of one confluent 6cm dish 
were equally distributed to 5-10 cryovials containing. Once the cells were 
centrifuged after dissociation the cell pellet was resuspended in the 
appropriate amount of cryopreservation medium, and 1 ml aliquots of the cell 
suspension were frozen in cryovials at -80 °C. ROCK inhibitor was added to 
the cryopreservation medium when EpiSC were frozen. For long term storage 
the cells were stored at -150 °C in liquid nitrogen. 
The cryopreserved cells were thawed quickly at 37 °C in a water bath until 
most of the content was liquid, and the cell suspension was diluted at least 
1:10 in the corresponding culture medium of the thawed cell type. The cells 
were centrifuged, the medium was aspirated thoroughly, and the cell pellet 
was resuspended in prewarmed culture medium. The EpiSC or ESC from one 
vial were seeded into one 6cm dish.   
 
3.2.6 Small Molecule Screening Assay 
 
96-well plates with black walls and clear bottoms were precoated with FCS for 
15 min at RT. The FCS was aspirated and the 96-well plates were washed  
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with 200 µl of PBS per well using a multichannel pipette. EpiSC were 
dissociated into single cells using accutase and the cells were seeded out at 
2000 cells per well in 150 µl of EpiSC CM. The plates were incubated for  
48 hrs at 37 °C. The culture medium was replaced by 90 µl of fresh CM and 
the compounds of the LOPAC library were added in 10 µl samples so that the 
final concentration of each compound was 10 µM. The cells were incubated 
with the compounds for six days at 37 °C. After the incubation the medium 
was thoroughly aspirated and 50 µl per well of trypsin was added without 
washing the cells and the plates were incubated for 30 min at 37 °C. The 
dissociation of the colonies was further facilitated through rocking and 
vortexing the plate, and pipetting up and down the trypsin cell suspension. 
Then 50 µl of MEF medium containing Hoechst nuclei dye was added to each 
well and the plates were read out by a high-content imager. The quantitative 
readout using high-content imaging was based on the number of single cells 
with a GFP intensity above a preset minimum value. The threshold for the 
GFP intensity was set according to the level in ESC. As a positive control, 
2i/LIF-supplied ESC medium was used, whereas EpiSC CM containing bFGF 
was used as negative control. The quality of the assay was validated using 
the Z-factor, which was calculated to be 0.57.  
 
3.2.7 Conversion of EpiSC 
 
EpiSC were plated either on %-irradiated MEF feeder cells or on FCS-coated 
tissue culture plates at low density (&10000 cells per well of 6-well plate) and 
cultured overnight in MEF-conditioned EpiSC medium supplemented with 
bFGF. The next day the EpiSC medium was replaced by the conversion 
medium. If not otherwise indicated the conversion medium consisted of MEF-
conditioned EpiSC medium containing 5 µM TR or AU52 without additional 
bFGF. The cells were cultured in the conversion medium for eight days, and 
after the first three days medium was changed every day. OCT4-GFP positive  
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colonies usually started to appear on day 6. On day 8 the cells were 
dissociated with trypsin and replated at low density on MEF feeder cells or on 
a gelatin-coated cell culture dish to allow single colony formation, and were 
cultured in standard ESC medium supplemented with PD. For the first 3-5 
passages the newly formed ESC-like colonies were manually selected, 
dissociated with trypsin, and replated in a new culture dish.     
 
3.2.8 FACS 
 
Tissue culture cells for flow cytometry analysis were first dissociated using an 
appropriate enzyme. ESC and converted EpiSC were dissociated using 
trypsin, for EpiSC accutase was used. Around one million cells were 
resuspended in 500 µl of cell culture medium and the cell suspension was 
passed through a 40 µm cell strainer to remove debris and undissociated 
tissue. DAPI dye was added to detect dead cells. The readout was based on 
OCT4-GFP expression.   
If cells were stained for the expression of PECAM1/CD31 usually one million 
of the dissociated cells was resuspended in 100 µl of 3% FCS in PBS. The 
conjugated antibody was added and the cell suspension was incubated on ice 
for 30 min with short vortexing disruptions after each 10 min. After the 
incubation the cells were washed twice with 300 µl of 3% FCS in PBS, 
resuspended in 500 µl of cell culture medium containing DAPI dye, and 
passed through a 40 µm cell strainer before they were submitted for analysis.  
 
3.2.9 Total RNA Isolation 
 
Total RNA from tissue culture cells was isolated using the RNAeasy 
Mini/Micro Kit (Qiagen) following the manufacturer's instructions that are 
briefly described here. Cells grown in a monolayer in a cell culture dish were 
lysed directly in the culture vessel using the RLT lysis buffer. The lysate was 
pipetted directly onto a QIAshredder spin column placed in a 2 ml collection  
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tube, and centrifuged for 2 min at maximum speed. One volume of 70% 
ethanol was added to the homogenized lysate, mixed well by pipetting, and 
applied to an RNeasy mini column placed in a 2 ml collection tube, and 
centrifuged for 15 s at 10000 rpm. The flow-through was discarded since the 
RNA was bound to the silica-gel membrane of the RNeasy mini column. The 
RNA was washed twice with RW1 buffer before DNAse I in Buffer RDD was 
pipetted directly onto the RNeasy silica-gel membrane for a 15 min incubation 
at RT. The RNA was washed once again with buffe RW1, and twice with 
buffer RPE. The RNA was eluted by pipetting a small amount of RNAse-free 
water directly onto the silica-gel membrane, and centrifugation for 1 min at 
10000 rpm. The concentration of RNA was determined using the NanoDrop 
spectrophotometer.     
 
3.2.10 cDNA Synthesis 
 
For qRT-PCR, 200 to 1000 ng of total RNA were used in one reverse 
transcription reaction. A 25 µl reaction mixture with up to 1 µg of total RNA 
consisted of 5 µl RT-buffer, 0.5 µl oligo-dT, 0.5 µl dNTP mix, 0.2 µl M-MLV 
reverse transcriptase, and water. The reaction mixture was incubated in a 
thermo cycler for 60 min at 42 °C, and then for 10 min at 75 °C to inactivate 
the enzyme. The 25 µl of cDNA that was made from 200 ng of total RNA was 
diluted by adding 675 µl of nuclease-free water before it was used in a qRT-
PCR reaction. The cDNA was stored at -20 °C, and the RNA was stored at  
-80 °C. 
 
3.2.11 qRT-PCR 
 
qRT-PCR was performed using the Applied Biosystems 7500 Real-Time PCR 
instrument. The 20 µl reaction mix contained 10 µl SYBR green PCR master 
mix, 7 µl of cDNA prepared as discribed under 3.2.9, and 3 µl of the primer 
mix. The primer mix was prepared by adding together 5 µl of a 100 mM  
3.     Experimental Part 
_____________________________________________________________________ 
! '(!
 
 
solution of each, the forward and reverse primer, and 190 µl of water. The 
reactions were performed over 40 cycles, and the relative expression levels 
were calculated using the 2-$$Ct method. Gapdh and Actb were used as 
housekeeping genes, and the expression levels were normalized to technical 
and biological reference samples. Primer sequences are shown under 3.1.6. 
 
3.2.12 Microarray Analysis 
 
Total RNA for global transcriptome microarray analysis was isolated as 
described under 3.2.9 using Qiagen RNeasy columns with on-column DNA 
digestion. 300 ng of total RNA per sample was used as input into a linear 
amplification protocol (Ambion) which involved synthesis of T7-linked double-
stranded cDNA and 12 hours of in vitro transcription incorporating biotin-
labelled nucleotides. The 2100 Bioanalyzer (Agilent) was used for quality 
control. Purified and labeled cRNA was then hybridized for 18h onto  Illumina 
MouseRef-8 v2 expression BeadChips following the manufacturer’s 
instructions. After washing as recommended, chips were stained with 
streptavidin-Cy3 (GE Healthcare) and scanned using the iScan reader 
(Illumina) and accompanying software. Samples were exclusively hybridized 
as biological replicates.  
For microarray data processing the bead intensities were mapped to gene 
information using BeadStudio 3.2 (Illumina). Background correction was 
performed using the Affymetrix Robust Multi-array Analysis (RMA) 
background correction model (Irizarry et al., 2003). Variance stabilization was 
performed using the log2 scaling and gene expression normalization was 
calculated with the method implemented in the lumi package of  
R-Bioconductor. Data post-processing and graphics was performed with in-
house developed functions in Matlab. Hierarchical clustering of genes and 
samples was performed with one minus correlation metric and the unweighted 
average distance (UPGMA) (also known as group average) linkage method. 
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3.2.13 DNA Isolation 
 
Tissue culture cells were lysed using the ATL buffer from the DNeasy Blood & 
Tissue kit. Proteinase K was added and the microcentrifuge tube was placed 
in a thermomixer at 55 °C for overnight incubation. One volume of nuclease-
free water was added and then one volume of a 
phenol:chloroform:isoamylalcohol mixture, and the content was mixed 
thoroughly. The tube was centrifuged for 10 min at 12000 rpm at RT, and the 
separated upper phase was transferred to a new tube. One volume of 
phenol:chloroform:isoamylalcohol was added, the content was mixed 
thoroughly, and centrifuged for 10 min at maximum at 20 °C, and the resulting 
upper phase was transferred to a new tube. Two volumes of ice-cold 96% 
ethanol and 1/10 volume of a 3 M sodium acetate solution were added and 
the sample was kept for 30 min at -80 °C.  After centrifugation for 15 min at 
10000 rpm at 5 °C the supernatant was removed, and the DNA pallet was 
washed with ice-cold 70% ethanol. After another centrifugation for 15 min at 
10000 rpm at 5 °C the supernatant was removed, and the DNA pellet was air-
dried. The DNA pellet was then dissolved in nuclease-free water by incubation 
at 55 °C in a thermomixer for six hours .    
 
3.2.14 DNA Methylation Analysis 
 
To determine DNA promoter methylation status, bisulfite conversion was 
carried out on 2 µg of isolated genomic DNA using the EpiTect Bisulfite kit 
(Qiagen) according to the manufacturer’s protocol. The two step protocol, 
consisting of bisulfite DNA conversion and cleanup of bisulfite converted DNA 
are briefly described here. DNA to be used in the bisulfite reactions was 
thawed. The required amount of Bisulfite Mix was dissolved by adding 800 µl 
RNase-free water to each aliquot. The Bisulfite Mix was completely dissolved 
by vortexing. The bisulfite reactions were prepared in 200 µl PCR tubes 
according to the instructions provided by the manufacturer. The PCR tubes  
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were closed tightly and mixed thoroughly at RT. The DNA protect buffer 
turned from green to blue indicating sufficient mixing and correct pH for the 
bisulfite conversion reaction. The bisulfite DNA conversion was performed in a 
thermal cycler following the program indicated by the manufacturer. After the 
bisulfite conversion was completed the PCR tubes containing the bisulfite 
reaction were briefly centrifuged, and then the complete bisulfite reaction was 
transferred to a clean 1.5 ml microcentrifuge tube. 560 µl of freshly prepared 
Buffer BL containing 10 µg/ml carrier RNA were added to each sample. The 
solutions were mixed by vortexing and then centrifuged briefly. Then, the 
entire mixture from each 1.5 ml microcentrifuge tube was transferred into the 
corresponding EpiTect spin column. The spin columns were centrifuged at 
maximum speed for 1 min. The flow-through was discarded. The spin column 
was then washed once with 500 µl of Buffer BW. 500 µl Buffer BD was added 
to each spin column, and incubated for 15 min at RT. The spin column was 
centrifuged at maximum speed for 1 min, the flow-through was discarded, and 
the spin column was washed twice with 500 µl of Buffer BW. To remove any 
remaining liquid the spin column was centrifuged at maximum speed for 1 min 
in a new 2 ml collection tube, and subsequently incubated for 5 min at 56 °C 
in a heating block. The purified DNA was then eluted with 20 µl Buffer EB and 
centrifugation. 
The bisulfite converted DNA was amplified by PCR using the primers provided 
under 3.1.7. Bisulfite PCR was performed using DNA proofreading 
polymerase according to manufacturer's instructions. 20 µl reaction mixtures 
comprised of DNA proofreading polymerase, primers for methylation analysis, 
bisulfite converted DNA, and nuclease-free water. The PCR cycling conditions 
were 95 °C for 5 min followed by 40 cycles (95 °C for 30 sec, Xoptimal °C for 
45 sec, 72 °C for 1 min) and a final extension step at 72 °C for 5 min. Optimal 
annealing temperature (Xoptimal °C) was empirically determined for each 
primer set using the Primer3web software.  
PCR products were purified using QIAquick gel extraction kit, cloned into the 
pCRII TOPO vector according to the manufacturer’s protocol, and  
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subsequently transformed into TOP10 Escherichia coli. Individual colonies 
were inoculated into LB medium containing Kanamycin (50 µg/ml) and 
cultured overnight in a 37 °C shaking incubator. Plasmids were extracted 
using the ZR plasmid miniprep kit.  
Individual clones were sequenced by GATC-biotech using the M13 primers 
(http://www.gatc-biotech.com/en/index.html). Sequences were analyzed using 
the Quantification Tool for Methylation Analysis (QUMA, 
http://quma.cdb.riken.jp).  
 
3.2.15 Immunocytochemistry 
 
Cells grown in a 12-well plate were rinsed with PBS and fixed with 4% 
PFA/PBS for 10 min at RT. The PFA solution was aspirated, the cells were 
rinsed with PBS, and permeabilized with 0.2% Triton X-100/PBS for 10 min at 
RT. The Triton X-100 solution was aspirated, the cells were rinsed with PBS, 
and the blocking solution, consisting of 2% BSA/5% FCS/PBS, was added for 
1 hour at RT. The blocking solution was aspirated, the cells were rinsed with 
PBS, and the cells were incubated with the primary antibody (given under 
3.1.5) either overnight at 5 °C, or for one hour at RT. The primary antibody 
was diluted as indicated under 3.1.5 in 0.5% BSA/PBS. The cells were 
washed three times rocking for 5 min with PBS, and the secondary antibody 
was applied for one hour at RT in a 1:1000 dilution in 0.5% BSA/PBS. The 
cells were washed three times rocking for 5 min with PBS. Hoechst dye was 
added during the second washing step. The cells were covered with mounting 
medium and a cover slide, and pictures were taken on a Leica fluorescense 
microscope. 
 
3.2.16 Alkaline Phosphatase Staining 
 
The staining solution was prepared by adding 40 µl of naphthol phosphate 
solution to 1 ml of Fast Red chromogen. Cells grown in a monolayer in a  
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culture vessel were rinsed with PBS and fixed with 4% PFA/PBS for 10 min at 
RT. The PFA solution was aspirated, the cells were rinsed with PBS, and 
covered with the staining solution. The cells were incubated with the staining 
solution for 15 min at RT in dark. The staining solution was aspirated, and the 
cells were rinsed with Milli-Q water and allowed to air-dry.   
 
3.2.17 Teratoma Assay and H&E Staining 
 
The teratoma assay was used to assess the in vivo pluripotency of cells. 
Cultured cells were dissociated into single cells using an appropriate enzyme, 
and one million cells were collected in about 250 µl of cell culture medium. 
The cell suspension was injected subcutaneously into the flanks of 
immunodeficient SCID mice. The development of the teratomas was carefully 
observed, and the mice were usually sacrificed 4-6 weeks following the 
injection. The teratomas were excised and fixed in 4% paraformaldehyde at 4 
°C overnight, and paraffin embedded at 4 °C until they were sectioned (4 µm) 
and stained with hematoxylin & eosin for histological analysis according to 
standard procedures.    
 
3.2.18 ESC Aggregation  
 
Cells were aggregated and cultured with denuded post-compacted eight-cell 
stage mouse embryos. Briefly, eight-cell embryos were flushed from 
[(C57BL/6 x C3H) F1 females x CD1 males] at 2.5 dpc and placed in M2 
medium.  Clumps of loosely connected cells (10-20 cells each) with short 
trypsin-treatment were chosen and transferred into microdrops of potassium 
simplex optimized medium (KSOM) with 10% FCS under mineral oil. Each 
clump was placed in a depression in the microdrop. Meanwhile, batches of 
30-40 embryos were briefly incubated in acidified Tyrode's solution until 
dissolution of their zona pellucida.  A single embryo was placed on the clump. 
All aggregates were assembled in this manner, and cultured overnight at  
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37 °C and 5% CO2. After 24 hours of culture, the majority of aggregates had 
formed blastocysts. 11-14 embryos were transferred into one uterine horn of a 
2.5 dpc pseudopregnant recipient.  
 
3.2.19 Kinase Profiling Assay and IC50 Determination 
 
The kinase profiling assay and the IC50 determination have been performed 
by the KinaseProfiler and IC50Profiler Services at Merck/Millipore, which at 
the time this thesis was written belonged to Eurofins. A radiometric assay was 
used for all protein kinases, and a FRET-based assay, called HTRF assay, 
was applied for the lipid kinases. The screening conditions and protocols used 
in the KinaseProfiler radiometric protein kinase assays and HTRF lipid kinase 
assays as provided by Merck/Millipore are briefly described here. 
            
Dilution buffer compositions prior to addition to reaction mix: 
 
• FAK:  
15 mM MOPS, 0.75 mM EDTA, 0.0075% Brij-35, 3.75% Glycerol, 150 
mM NaCl, 0.1% !-mercaptoethanol, 1 mg/mL BSA 
 
• PKC", PKC!I, PKC!II, PKC#, PKC$, PKC%, PKCµ, PKC&, PKC': 
20 mM HEPES, 0.03% Triton X-100 
 
• CK2, CK2"2: 
20 mM HEPES, 0.15 M NaCl, 0.1 M EDTA, 5 mM DTT, 0.1% Triton X-
100, 50% Glycerol 
 
• MEK1: 
25 mM TRIS, 0.1 mM EGTA, 0.1% !-mercaptoethanol, 1 mg/mL BSA 
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• mTOR: 
500 mM HEPES, 10 mM EGTA, 0.1% Tween 20 
 
• PDK1: 
50 mM TRIS, 0.1% !-mercaptoethanol, 1 mg/mL BSA 
 
• JNK1"1, JNK2"2, JNK3, ROCK-II: 
50 mM TRIS, 0.1 mM EGTA, 0.1% !-mercaptoethanol, 1 mg/mL BSA 
 
• Lyn, MAPK1, MAPK2, MKK4, MKK6, MKK7!, Syk: 
50 mM TRIS, 0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% !-
mercaptoethanol,  
1 mg/mL BSA 
 
• all other profiled kinases: 
20 mM MOPS, 1 mM EDTA, 0.01% Brij-35, 5% Glycerol,  
0.1% !-mercaptoethanol, 1 mg/mL BSA 
 
• The dilution buffer composition for the lipid kinase assays is 
proprietary. 
 
All compounds were prepared to 50x final assay concentration in 100% 
DMSO. This working stock of the compound was added to the assay well as 
the first component in the reaction, followed by the remaining components as 
detailed in the general assay protocols below. In the standard KinaseProfiler 
service, there was no pre-incubation step between the compound and the 
kinase prior to initiation of the reaction. The positive control wells contained all 
components of the reaction, except the compound of interest; however, 
DMSO (at a final concentration of 2%) was included in these wells to control 
for solvent effects. The blank wells contained all components of the reaction, 
with a reference inhibitor replacing the compound of interest. This abolished  
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kinase activity and established the base-line (0% kinase activity remaining). 
The reference inhibitors used to generate the blank signal for each kinase are 
given below. For lipid kinase assays, the blank wells were generated by 
omitting the enzyme (rather than by including a reference inhibitor to abolish 
the signal). 
 
General kinase assay protocol for the radiometric assay: 
 
The majority of the kinases was incubated with 8 mM MOPS pH 7.0, 0.2 mM 
EDTA, 50 µM EAIYAAPFAKKK, 10 mM MgAcetate and [#-33P-ATP] (specific 
activity approx. 500 cpm/pmol, concentration as required). The reaction was 
initiated by the addition of the MgATP mix. After incubation for 40 minutes at 
room temperature, the reaction was stopped by the addition of 3% phosphoric 
acid solution. 10 µl of the reaction was then spotted onto a P30 filtermat and 
washed three times for 5 minutes in 75 mM phosphoric acid and once in 
methanol prior to drying and scintillation counting. Modifications to this 
protocol include the buffer composition (see above) and the substrate and 
substrate concentration. 
 
General kinase assay protocol for the FRET-based assay: 
 
The lipid kinases were incubated in assay buffer containing 25 µM 
phosphatidylinositol 4-phosphate/75 µM phosphatidylserine and MgATP 
(concentration as required). The reaction was initiated by the addition of the 
ATP solution. After incubation for 30 minutes at room temperature, the 
reaction was stopped by the addition of stop solution containing EDTA and 
biotinylated phosphatidylinositol 4,5-bisphosphate. Finally, detection buffer 
was added, which contained europium-labelled anti-GST monoclonal 
antibody, a GST-tagged PH domain and streptavidin allophycocyanin. The 
plate was then read in time-resolved fluorescence mode and the homogenous  
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time-resolved fluorescence (HTRF) signal was determined according to the 
formula HTRF = 10000 x (Em665nm/Em620nm). 
 
3.2.20 Luciferase Assays 
 
To assess the relative Oct4 enhancer activities luciferase vectors containing 
the proximal (PE) and distal (DE) enhancers in the pGL3-promoter were used 
(Greber et al., 2010). The investigated cells were transfected as single cells 
with the luciferase vectors together with a renilla vector by Amaxa 
nucleofection (Program A-23, 4 µg of DNA, 1x106 cells). The cells were 
cultured feeder-free, and EpiSC were cultured with the ROCK inhibitor after 
nucleofection. 48 hours after the transfection the cells were assayed using the 
Dual-Glo Luciferase assay according to the manufacturer's instructions. The 
read out was performed in 96-well plates with white walls and flat, white 
bottoms. The luciferase values were normalized to the renilla values and 
divided by the signals for the empty vector. 
The TOP/FOP luciferase assay was performed in a 96-well cell culture plate. 
EpiSC were plated feeder-free on FCS-coated surface at a density of  
5000 cells/well. The next day, the cells were transfected in Opti-MEM medium 
with 100 ng per well of the TOP/FOPFlash vectors together with 0.4 ng per 
well of a renilla vector using Lipofectamin 2000 according to the 
manufacturer's instructions. After 24 hours the cells were treated with 10 µM 
AU52, 3 µM CH, and DMSO control. The cells were incubated for 24 hours 
and subsequently reporter activity was quantified using the Dual-Glo 
Luciferase assay. The firefly signals were normalized to renilla luciferase 
activity, and then the TOP/FOP ratio was calculated. 
 
3.2.21 shRNA-Based Gene Knockdown 
 
The MISSION TRC shRNA constructs were received as bacterial glycerol 
stocks and were used with packaging plasmids to produce lentiviral  
3.     Experimental Part 
_____________________________________________________________________ 
! ('!
 
 
transduction particles. Bacterial cultures were amplified from the glycerol 
stocks for use in purification of the shRNA plasmid DNA using the ZR plasmid 
miniprep kit and the NucleoBond Xtra plasmid midi/maxiprep kit following the 
manufacturers' instructions. HEK293T cells were used as packaging cells for 
lentiviral particle production by co-transfection with compatible packaging 
plasmids using FuGENE 6 following standard procedures. EpiSC were 
seeded as single cells on FCS-coated tissue culture dishes at low density 12 
hours prior to the infection. The attached single cells were transduced by the 
lentiviral particles overnight. The transduction medium was replaced by 
normal EpiSC MEF-conditioned medium, and the cells were cultured 
overnight before puromycin selection was initiated. Knockdown efficiency was 
assessed by qRT-PCR.     
 
3.2.22 Western Blotting 
 
Protein isolation was performed on ice to avoid protein degradation. Adherent 
cells were washed with cold PBS, and lysed with RIPA lysis buffer containing 
protease inhibitors (250 µl per well of 6-well plate). Cells were scraped from 
the culture dish using a pre-cooled cell scraper and placed into a 
microcentrifuge tube. To shear DNA to reduce viscosity the sample was 
sonicated 3 times for 15 seconds, and subsequently centrifuged at 16000g for 
20 min at 4 °C. The supernatant was transferred to a new tube, and the pellet 
was discarded. A Bradford assay with BSA as protein standard was used to 
determine the protein concentration. Protein concentrations of the samples 
were equalized by adding lysis buffer, and the lysates were boiled in Laemmli 
sample buffer at 95 °C for 5 min to denature the protein. Equal amounts of 
protein (20 µg) were loaded into the wells of an SDS-PAGE gel (gel 
percentage depending on the size of the protein), and the electrophoresis was 
run in running buffer at 100-150 V to complete the run in about 1 hour. The 
proteins were blotted on a PVDF membrane overnight in a cold room at a  
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constant current of 10 mA. The membrane was blocked in 5% milk powder in 
TBST at RT for 1 hr. The primary antibody was diluted in the blocking 
solution, and the membrane was incubated overnight at 4 °C. The blot was 
rinsed 3 times for 5 min with TBST and incubated in blocking solution 
containing the HRP-conjugated secondary antibody for 1 hour at RT. The 
membrane was rinsed 3 times for 5 min with TBST, and the 
chemiluminescence signal was captured using the chemiluminescent HRP 
substrate and ECL Hyperfilm in an autoradiography cassette. The films were 
developed and scanned in for digital editing. The primary antibodies for 
Western blotting are given under 3.1.5. 
 
 
• RIPA lysis buffer: 
50 mM Tris-HCl pH 8.0 
150 mM NaCl 
0.1% Triton X-100 
0.5% sodium deoxycholate 
0.1% sodium dodecyl sulphate (SDS) 
1 mM sodium orthovanadate 
1 mM NaF 
Protease inhibitors tablet 
 
• Laemmli sample/loading buffer 
4% SDS 
10% 2-mercaptoethanol 
20% glycerol 
0.004% bromophenol blue 
0.125 M Tris-HCl pH 6.8 
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• Running buffer 
25 mM Tris pH 8.3 
190 mM glycine 
0.1% SDS 
 
• TBST 
20 mM Tris pH 7.5 
150 mM NaCl 
0.1% Tween 20 
 
3.2.23 Zebrafish Developmental Assay 
 
Zebrafish were maintained in a recirculating aquaculture system under 
standard laboratory conditions at 27 °C. For mating, a male and a female fish 
were kept overnight in a 1 liter tank, separated by a grid. The next morning, as 
the grid was removed, the female laid eggs that were immediately fertilized by 
the male´s sperm. Embryos were harvested and kept in petri dishes filled with 
1 x E3 embryo medium at 28.5 °C. They were staged by hours post 
fertilization (hpf) at 28.5 °C. Wild type embryos were dechorionated at 5 hpf 
and kept in E3 medium in 2% agarose/E3-coated petri dishes. At 7 hpf the 
medium was exchanged to E3 medium supplemented with either 20 µM IWR-
1, 3 µM CH, 5 µM TR, 5 µM AU52, or the same volume of DMSO as control. 
Embryos were incubated at 28.5 °C and imaged at 48 hpf with a 
stereomicroscope. 60 x E3: 17.2 g NaCl, 0.75 g KCl, 2.9 g CaCl2(2H2O,  
4.9 g MgSO4(7H2O, ddH2O up to 1 liter. 
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4. Results 
 
 
4.1 Late-Stage EpiSC are Recalcitrant as They Do Not Revert Under 
the 2i/LIF Condition 
 
EpiSC-GOF18  contain a GFP transgene that is driven by at least three 
regulatory elements of the Oct4 gene (Yeom et al., 1996). The upstream area 
contains two enhancers, namely the distal enhancer (DE) and the proximal 
enhancer (PE), as well as a TATA-less promoter. In ESC-OG2, the GFP 
reporter depends on the DE of Oct4 for transcription, i.e., the transgene lacks 
the proximal enhancer (Oct4-$PE-GFP) (Yeom et al., 1996). The DE of Oct4 
contains a dense binding locus for key ESC-specific transcription factors 
(Chen et al., 2008). EpiSC preferentially utilize the PE over the DE, and the 
Oct4-$PE-GFP is active only in ESC, and not in EpiSC—both findings 
suggesting that EpiSC must lack some key ESC-specific transcription factors 
(Tesar et al., 2007; Yeom et al., 1996). The two Oct4 reporter lines (GOF18, 
which has the entire Oct4 regulatory region, and OG2, which lacks the 
proximal enhancer, PE) were used to study naïve pluripotency (Yeom et al., 
1996). Naïve pluripotent cells of both the GOF18 and OG2 reporter lines 
express GFP when cultured in ESC conditions (Figures 1, ESC samples). The 
corresponding primed pluripotent cells when cultured in EpiSC conditions do 
not express GFP, except for the small subpopulation which was previously 
shown to be chimera competent (Han et al., 2010) (Figures 1, EpiSC 
samples).  
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Figure 1. OCT4-GFP expression in naive and primed pluripotent stem cells. 
Upper panel: Percentage of OCT4-GFP–positive cells in EpiSC-GOF18 (left),  
EpiSC-OG2 (middle), and ESC-OG2 (right) as measured by FACS. Lower panel: 
Morphology and OCT4-GFP expression in ESC-OG2, EpiSC-GOF18, and EpiSC-
OG2 (Scale bar: 300µm). 
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Global gene expression analysis revealed that EpiSC-GOF18 exhibited a 
gene expression pattern distinct from that of ESC-OG2 (Figure 2). Certain 
genes were specifically expressed in ESC that were not present in EpiSC, 
such as Zfp42/Rex1 and Dppa3. Since they respresent the naïve cell type that 
was originally derived from the ICM, they were termed ICM markers. The 
bioinformatics analysis of microarray data was performed by Dr Marcos Jesus 
Arauzo Bravo.  
 
 
 
 
 
Figure 2. Scatter plot of global gene expression microarrays comparing  
EpiSC-GOF18s with ESC-OG2.  
The black lines delineate the boundaries of 4-fold difference in gene expression 
levels. Genes highly expressed in EpiSC samples compared with ESC samples are 
shown as red dots; those less expressed are shown as green dots. Positions of the 
pluripotent cell marker Zfp42/Rex1 and the germ cell marker Dppa3/Stella are 
indicated as orange dots. The color bar to the right indicates the scattering density; 
the higher the scattering density, the darker the blue color. Gene expression levels 
are depicted on log2 scale.  
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Quantitative RT-PCR analysis confirmed that a set of genes including Klf4, 
Rex1, Stella, Esrrb, Dppa4 and Dppa5 were expressed at much lower levels 
in EpiSC compared with ESC, whereas lineage specific markers such as  
T-brachyury, Fgf5 and Fgf8 were expressed at higher levels (Figure 3).  
 
 
 
 
 
Figure 3. Comparison of gene expression patterns in EpiSC versus ESC. 
Expression levels are normalized to the ESC levels (Data represent mean ± SD of 
triplicates; n = 3).  
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As reported previously (Han et al., 2010), when unsorted EpiSC-GOF18 
containing OCT4-GFP–positive and –negative cells were cultured in 2i/LIF, I 
observed an increase in OCT4-GFP–expressing cells that resembled ESC 
(about 6-fold; compare left panels of Figures 1 and 4, vehicle control in lower 
left panel of Figure 4). When sorted OCT4-GFP–negative EpiSC-GOF18 or 
EpiSC-OG2 were cultured under the same conditions, namely 2i/LIF, I did not 
detect an increase in OCT4-GFP–positive cells, demonstrating that these 
GFP-negative cells were recalcitrant to conversion (Figure 4, compare middle 
panels for EpiSC-GOF18 and right panels for EpiSC-OG2).  
 
 
 
 
 
Figure 4. FACS analysis of 2i/LIF-induced ESC conversion. 
Upper panel) Percentage of OCT4-GFP–positive cells after ESC conversion with 
PD/CH/LIF in unsorted EpiSC-GOF18 (left), sorted OCT4-GFP–negative EpiSC-
GOF18 (middle), and EpiSC-OG2 (right) as measured by FACS. Lower panel) 
DMSO controls for the conversion with PD/CH/LIF in unsorted EpiSC-GOF18 (left), 
sorted OCT4-GFP–negative EpiSC-GOF18 (middle), and EpiSC-OG2 (right) as 
measured by FACS. 
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The 2i/LIF converted cells could be maintained under ESC culture condition, 
exhibited an  ESC morphology, and also showed increased expression of the 
ICM/ESC marker Rex1, which was neither increased in FACS-sorted  
OCT4-GFP–negative cells, nor in EpiSC-OG2  (Figure 5).  
 
 
 
 
 
 
Figure 5. 2i/LIF converted EpiSC-GOF18. 
Left panel) OCT4-GFP expression in PD/CH/LIF-converted EpiSC-GOF18 (Scale 
bar: 250µm). Right panel) Expression of the ICM marker gene Rex1 (Zfp42) in 
unsorted EpiSC, OCT4-GFP–negative EpiSC, and  EpiSC-OG2 after conversion with 
PD/CH/LIF compared to EpiSC and ESC. Expression levels are normalized to the 
ESC levels (Data represent mean ± SD of triplicates; n = 3). 
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4.2 Small Molecule Screen Identifies Triamterene (TR) 
 
To identify small molecules capable of converting recalcitrant  
late-stage EpiSC into an ESC-like state, I developed a screening platform in a 
96-well format (Figure 6). Three crucial parameters had to be optimized for 
establishing a robust and reproducible assay. I plated 2,000 single EpiSC per 
well and cultured the plates under EpiSC culture conditions (mouse 
embryonic fibroblast [MEF] conditioned medium containing bFGF) for two 
days to allow the cells to attach and start forming colonies. Plating 2,000 
cells/well proved optimal in terms of growth characteristics, efficiency of the 
positive control (2i/LIF), and standard deviation of the readout. Moreover, I 
determined that six days of incubation resulted in optimum values for the 
positive control.  
 
 
 
 
 
Figure 6. Schematic representation of the assay workflow. 
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The quantitative readout using high-content imaging was based on the 
number of single cells with a GFP intensity above a preset minimum value 
which was based on the OCT4-GFP intensity in ESC (Figure 7).  
 
 
 
Figure 7. Readout system based on consequent fluorescence imaging for 
Hoechst nuclei stain (left) and OCT4-GFP (right) with Arrayscan' .  
(Scale bar: 100 µM) 
 
The threshold for the GFP intensity was set according to the level in ESC. As 
a positive control, I used 2i/LIF-supplied ESC medium. As a negative control I 
used EpiSC culture medium, i.e. MEF conditioned medium containing bFGF, 
in which spontaneous conversion was not observed  (Figure 8).  
 
 
 
Figure 8. Positive and negative controls of the small-molecule screening assay 
as measured by the Arrayscan' .  
 ESC as positive controls, were cultured under PD/CH/LIF condition;  EpiSC as 
negative controls, were kept under EpiSC culture conditions, i.e. on FCS-coated 
surface with MEF-conditioned medium and bFGF. 
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The quality of the assay was validated using the Z'-factor, which was 
calculated to be 0.57 (Zhang et al., 1999) (Figure 9).  
 
 
 
Figure 9. Z-factor of the developed small-molecule screening assay. (Data 
represent mean ± SD of triplicates; n = 3; p < 0.001).  
 
Then the LOPACTM library containing about 1,200 pharmacologically active 
compounds was screened at 10 µM screening concentration, and an active 
compound capable of inducing OCT4-GFP expression in EpiSC under EpiSC 
culture conditions was identified (Figure 10).  
 
 
 
Figure 10. Hit compound Triamteren. 
The hit compound Triamterene was located in rack number 15, position H07 of the 
LOPAC' library. 
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The hit compound was found to be a pteridine derivative known as 
Triamterene (TR), which blocks the epithelial sodium channel (ENaC), and is 
therefore used as a diuretic in the treatment of hypertension (Figure 11) 
(Busch et al., 1996). I subsequently evaluated the ability of the hit compound 
to convert late-stage EpiSC into an ESC-like state.  
 
 
 
 
 
Figure 11. Chemical structure of the hit compound Triamterene. 
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4.3 TR Induces ESC Conversion of Recalcitrant EpiSC   
 
TR was intially identified using unsorted EpiSC-GOF18. Next I tested the 
effect of TR on the recalcitrant OCT4-GFP–negative fraction of GOF18 cells. 
After culturing the OCT4-GFP–negative EpiSC-GOF18 with TR for seven 
days, flow cytometry analysis revealed a strong induction of OCT4-GFP 
expression, despite  the presence of bFGF and ActivinA (Figure 12 left panel). 
Furthermore, TR induced OCT4-GFP reactivation in EpiSC-OG2 with an 
efficiency comparable to that of the sorted OCT4-GFP-negative EpiSC-
GOF18 (Figure 12, compare left and right panels).  
 
 
 
 
 
 
Figure 12. Triamterene induces ESC conversion in recalcitrant  
late-stage OCT4-GFP–negative EpiSC-GOF18 and EpiSC-OG2. 
Percentage of OCT4-GFP–positive cells after treatment with Triamterene in sorted 
OCT4-GFP–negative EpiSC-GOF18 (left) and EpiSC-OG2  (right) as measured by 
FACS. 
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Clonal lines from the TR-reverted EpiSC-GOF18 ESC-like cells (TR-GOF18) 
were maintained for a prolongued period in ESC medium containing LIF in the 
absence of TR, and were passaged as single cells using trypsin. The cells 
exhibited a cell morphology and OCT4-GFP expression similar to ESC (Figure 
13).  
 
 
 
Figure 13. Morphology and OCT4-GFP expression in clonally expanded 
converted TR-GOF18 and TR-OG2 cells. 
 (Scale bar: 200µm).  
 
Reverted cells from both EpiSC-GOF18 and EpiSC-OG2 and ESC were also 
similar with respect to ALP expression and their proliferation rates (Figure 14).  
 
 
 
Figure 14. AP expression and growth curves of TR-GOF18 and TR-OG2 cells. 
Left panel) Expression of ALP in converted TR-GOF18 cells (Scale bar: 200µm). 
Right panel) Comparison of cell growth curves of TR-GOF18 and TR-OG2 cells with 
ESC. 
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Moreover, when cultured in the presence of CM/FGF, TR-converted cells 
dramatically changed their morphology toward bigger flat colonies, and also 
lost OCT4-GFP expression, two features consistent with an EpiSC phenotype 
(Figure 15).  
 
 
 
Figure 15. Morphology and OCT4-GFP expression of TR-GOF18 cells cultured 
under ESC conditions (KOES/LIF) and EpiSC conditions (CM/FGF). 
(Scale bar: 300µm). 
 
Additionally, TR-converted EpiSC (re)-expressed ESC-specific markers, such 
as Rex1, Stella, Klf2, Klf4  and Esrrb (Figure 2B). In contrast, genes 
upregulated in EpiSC, such as T-brachyury, Fgf5, and Fgf8, were 
downregulated in TR-induced cells.  
 
 
 
Figure 16. Comparison of gene expression patterns in ESC, TR-GOF18 cells, 
and EpiSC. 
Expression levels are normalized to those of EpiSC (Data represent mean ± SD of 
triplicates; n = 3). 
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Most importantly, global gene expression analysis showed obvious 
assimilation of the gene expression profiles between TR-converted cells and 
ESC (Figure 17; see also Figure 29). The bioinformatics analysis of 
microarray data was performed by Dr Marcos Jesus Arauzo Bravo. 
 
 
 
Figure 17. Scatter plot of global gene expression microarrays comparing TR-
GOF18 cells with ESC. 
The black lines delineate the boundaries of 4-fold difference in gene expression 
levels. Genes highly expressed in TR-GOF18 samples compared with ESC samples 
are shown as red dots; those less expressed are shown as green dots. Positions of 
the pluripotent cell marker Zfp42/Rex1 and the germ cell marker Dppa3/Stella are 
indicated as orange dots. The color bar to the right indicates the scattering density; 
the higher the scattering density, the darker the blue color. Gene expression levels 
are depicted on log2 scale. 
 
Then the ability of TR to convert EpiSC lines (T9 and C1a1), which were 
previously shown to be basically resistant to media-induced conversion using 
2i/LIF, was assessed (Bernemann et al., 2011). TR efficiently induced the 
reactivation of ESRRB and KLF4 proteins in EpiSC-T9 and EpiSC-C1a1, 
promoted a change in morphology to small dome-shaped colonies, and 
upregulated Pecam1 (Figure 18). The immunocytochemical analysis of TR-
converted EpiSC-T9 and EpiSC-C1a1 was performed by Dr Miao Zhang. 
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Figure 18. Immunocytochemical analysis of KLF4, ESRRB, and PECAM1 
expression in TR-converted recalcitrant late-stage EpiSC. 
Upper panel) Immunofluorescence analysis for the ICM markers Klf4 and Esrrb in the 
TR-converted EpiSC lines C1a1 and T9 (Scale bar: 200µm).  Lower panel) 
Percentage of Pecam1–positive (CD31) cells after treatment of EpiSC-GOF18, 
EpiSC-OG2, EpiSC-T9, and EpiSC-C1a1 with Triamterene as measured by FACS. 
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The effectiveness of TR to re-instate naïve pluripotency in EpiSC was further 
tested using an X-Chromosome-GFP reporter in female EpiSC. Culturing 
these EpiSC in ESC media containing LIF did not reactivate XChr-GFP on the 
silent X-chromosome, consistent with lack of reprogramming, whereas TR 
successfully promoted XChr-GFP reactivation (Figure 19). Taken together, TR 
induced the efficient conversion of recalcitrant late-stage EpiSC toward a 
cellular state that is similar to that of ESC. The immunocytochemical analysis 
of TR-converted EpiSC-T9 and EpiSC-C1a1 was performed by Dr Miao 
Zhang. 
 
 
 
 
 
Figure 19. TR-induced X-Chromosome reactivation in EpiSC. 
Upper panel) X-chromosome reactivation and immunofluorescence analysis for the 
ICM marker Esrrb after TR-conversion (Scale bar: 200µm).  
Lower panel) X-Chromosome reactivation induced by TR as compared to LIF 
treatment alone (Scale bar: 200µm). 
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4.4 Combined Treatment With TR/PD Improves the Transition to Naïve 
Pluripotency 
 
Althought TR-converted cells and ESC had many traits in common, the clonal 
populations displayed some OCT4-GFP-negative cells, which are not 
observed to such an extend in ESC cultured in KO-DMEM/KOSR/LIF (Figure 
20, compare left and middle panels). In order to overcome this deficiency, I 
treated the TR-converted cells with a select set of chemical inhibitors known 
to support ESC self-renewal/cell reprogramming as well as a collection of 
compounds synthesized in house (Nie et al., 2012). I found that culturing the 
TR-converted cells in KO-DMEM/KOSR/LIF, together with the MEK inhibitor 
PD0325901 (PD) dramatically increased the proportion of OCT4-GFP-positive 
cells (Figure 20, compare middle and right panels).  
 
 
 
 
 
 
Figure 20. Percentage of OCT4-GFP–positive cells in ESC, TR-GOF18 cells, and 
TR/PD-converted cells. 
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These TR/PD-converted cells and ESC were indistinguishable wth respect to 
cell morphology, growth characteristics, AP activity and OCT4-GFP 
expression (Figure 21).  
 
 
 
 
 
Figure 21. Morphology, OCT4-GFP expression, and ALP expression in ESC,  
TR-GOF18 cells, and TR/PD-converted cells grown on a MEF feeder layer and 
on a gelatin-coated surface. 
(Upper scale bar: 350µm, lower scale bar: 5mm). 
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At the molecular level, TR-GOF18 cells clearly expressed ICM-specific 
markers such as Rex1, Stella, and Esrrb which are not expressed in EpiSC 
(Figures 16 and 22). However, the expression levels of several ICM markers, 
such as Sox2, Klf4, Dppa4 and Dppa5 did not reach those of ESC (Figures 16 
and 22). On the other hand, some lineage markers, including T, Fgf5, and 
Fgf8 were still higher expressed than in ESC (Figures 16 and 22). This 
deficiency could be overcome by ERK inhibition in TR-GOF18 cells (Figure 
22). TR/PD-converted cells (re)-expressed ESC-specific markers, while 
EpiSC markers were downregulated (Figure 22). 
 
 
 
 
 
Figure 22. Comparison of gene expression patterns in ESC, TR-GOF18 cells, 
EpiSC, and TR/PD-converted cells. 
Expression levels are normalized to those of EpiSC (Data represent mean ± SD of 
triplicates; n = 3). 
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In contrast to EpiSC, colonies of TR/PD-converted cells exhibited 
homogeneously expressed protein levels of Sox2, Nanog, and Stella (Figure 
23). The immunocytochemical analysis of TR-converted EpiSC-T9 and 
EpiSC-C1a1 was performed by Dr Miao Zhang. 
 
 
 
  
Figure 23. Immunofluorescence analysis for SOX2, NANOG, and STELLA 
(DPPA3) in ESC, TR-GOF18 cells, EpiSC, and TR/PD-converted cells. DAPI was 
used for DNA staining. 
(Scale bar: 350µm). 
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ESC preferentially use the distal enhancer (DE) to drive Oct4 expression, 
while EpiSC use the proximal enhancer (PE) (Tesar et al., 2007; Yeom et al., 
1996). Using a luciferase assay, I compared Oct4 enhancer activity in the 
converted cells with that of ESC and EpiSC. The PE/DE ratio in TR/PD-
converted cells was tilted toward the preferential use of the Oct4 DE, 
reminiscent of ESC, but in contrast to EpiSC (Figure 24).  
 
 
 
 
 
 
 
Figure 24. Evaluation of the Oct4 enhancer activity in ESC, TR-GOF18 cells, 
EpiSC, and TR/PD-converted cells. 
Relative luciferase activity was normalized to the activity of an empty vector (Data 
represent mean ± SD of triplicates; n = 3; p < 0.001). 
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In accordance, TR/PD cells exhibited a global gene expression pattern that 
closely resembled the one of ESC (Figure 25, see also Figures 27 and 28). 
The bioinformatics analysis of the microarray data was performed by Dr 
Marcos Jesus Arauzo Bravo. 
 
 
 
 
 
Figure 25. Scatter plot of global gene expression microarrays comparing 
TR/PD cells with ESC. 
The black lines delineate the boundaries of 4-fold difference in gene expression 
levels. Genes highly expressed in TR/PD samples compared with ESC samples are 
shown as red dots; those less expressed are shown as green dots. Positions of the 
pluripotent cell marker Zfp42/Rex1 and the germ cell marker Dppa3/Stella are 
indicated as orange dots. The color bar to the right indicates the scattering density; 
the higher the scattering density, the darker the blue color. Gene expression levels 
are depicted on log2 scale. 
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Next, the responsiveness of the reverted cells to ESC- and EpiSC-related 
signaling pathways was assessed (Figure 26). EpiSC are dependent on 
TGF!/SMAD2/3 signaling, whereas ESC require stimulation of the LIF/STAT3 
pathway for their propagation. Inhibition of LIF/STAT3 signaling in ESC 
induces differentiation, i.e. pluripotency markers are downregulated, and early 
differentiation markers upregulated as compared to the untreated control 
(Figure 26 left panel, see ESC+JAKi). In contrast to that, EpiSC differentiation 
is induced when TGF!/SMAD2/3 signaling is inhibited (Figure 26 right panel, 
see EpiSC+SB). Upon inhibition of these two pathways TR/PD cells reacted in 
both cases similar to ESC and different from EpiSC which indicates a switch 
in the signaling pathways toward those related to naïve pluripotency (Figure 
26, see TR/PD+JAKi in left panel, and TR/PD+SB in right panel). Notably, TR-
converted cells exerted in both cases a more moderate response than ESC 
and TR/PD-converted cells (Figure 26, see TR-GOF18+JAKi in left panel, and 
TR-GOF18+SB in right panel).  
 
 
 
 
 
 
Figure 26. RT-qPCR analysis of the effects of LIF/STAT3 (left) and SMAD2/3 
(right) inhibition in ESC, TR-GOF18 cells, EpiSC, and TR/PD-converted cells. 
(Data represent mean ± SD of triplicates; n = 3). 
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4.5 Germline Competence is Restored in TR/PD-Converted Cells  
 
The converted cells were compared to EpiSC and ESC by global gene 
expression analysis. The heat maps of TR/PD cells were very similar to those 
of ESC (Figures 27). The bioinformatics analysis of the microarray data was 
performed by Dr Marcos Jesus Arauzo Bravo. 
 
 
 
Figure 27. Heat map of global gene expression patterns in ESC, TR-GOF18 
cells, EpiSC, and TR/PD-converted cells. 
The color bar at top codifies the gene expression in log2 scale. Red and blue colors 
indicate high and low gene expression levels, respectively. 
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The close correlation between TR/PD cells and ESC was also confirmed by 
hierarchical clustering analysis (Figure 28).  The bioinformatics analysis of the 
microarray data was performed by Dr Marcos Jesus Arauzo Bravo. 
 
 
 
 
 
Figure 28. Hierarchical clustering shows that TR/PD-converted cells 
cluster close to ESC. 
 
 
The most significantly differentially expressed genes between TR-converted 
and TR/PD cells give insight into the specific changes at the genetic level that 
distinguish the two cell types (Figure 29). For example, the ICM markers 
Dppa5, Esrrb, Dppa4, Klf2, and Nr5a2 are expressed in TR-GOF18 cells at 
levels comparable to those in ESC. Other ICM markers, such as Tcl1, Tbx3, 
and Klf4, are also strongly induced in TR-GOF18 cells as compared to EpiSC, 
but reach the expressio levels of ESC only upon addition of PD. MEK 
inhibition also results in the suppression of early differentiation markers, such 
as Fgf5 and Fgf8, which were still elevated in TR-GOF18 cells.    
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Figure 29. The 75 most significantly differentially expressed genes among the 
four samples EpiSC (GOF18), TR-GOF18, TR/PD and  
ESC (OG2). 
The color bar at top codifies the gene expression in log2 scale. Red and blue colors 
indicate high and low gene expression levels, respectively. 
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Then, it was assessed whether the aforementioned switch in gene expression 
was accompanied by a global change in the methylation state of TR/PD-
converted cells. Consistent with the gene expression data (Figures 3, 16, 22), 
the endogenous Oct4 promoter was completely unmethylated in both ESC 
and EpiSC, while the OCT4-GFP transgene promoter was mainly 
unmethylated in ESC and highly methylated in EpiSC (Figure 30). In TR/PD 
cells the OCT4-GFP transgene promoter was basically unmethylated, 
whereas in TR-converted cells the transgene promoter was only partially 
unmethylated. Demethylation was also observed for other marker genes 
analyzed in TR/PD-converted cells (Figure 30). Analysis of DNA methylation 
was performed by Dr Kee Pyo Kim. 
 
 
 
 
 
 
Figure 30. DNA methylation status of the promoter regions of ICM marker 
genes in ESC, TR-GOF18 cells, EpiSC, and TR/PD-converted cells. 
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Following global gene expression and methylation analysis, in vivo 
differentiation assays were used to functionally characterise the reverted cells. 
TR/PD-converted cells gave rise to teratomas containing tissues of all germ 
layers (Figure 31). Cell were injected, and teratomas were excised by Dr 
Davood Sabour.  
 
 
 
Figure 31. Teratoma assay with TR/PD cells. 
Upper panel) Representative image of a teratoma derived from TR/PD cells in a 
teratoma assay. Lower panel) Representative tissues of ectodermal (skin 
epithelium), mesodermal (muscle), and endodermal (gut-like) lineages in teratomas 
obtained from TR/PD-converted cells (Scale bar: 50µm). 
 
Most importantly, upon injection into blastocysts, TR/PD-converted cells 
showed successfull integration into the ICM, and consequently germline 
contribution (Figure 32).  
 
 
 
Figure 32. Germline contribution of TR/PD cells. 
ICM integration of TR/PD-converted cells in blastocyst (left, scale bar: 50µm), 
embryonic day (E)14.5 pups obtained after embryo transfer (middle), and 
germline contribution of TR/PD-converted cells (right, scale bar: 450µm). 
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4.6 TR Targets CK 1!/"   
 
Then, efforts were focused on the identification of the molecular target of TR,  
a well-known ENaC inhibitor (Busch et al., 1996). Amilorid, another 
structurally diverse ENaC inhibitor failed to induce OCT4-GFP expression in 
EpiSC-GOF18, thus ruling out ENaC as the effective target of TR-induced 
ESC conversion (Figure 33) (Canessa et al., 1994).    
 
 
 
 
 
Figure 33. ENaC and PI3K inhibition in EpiSC. 
Influence of ENaC and PI3K inhibitors on the induction of OCT4-GFP expression in 
EpiSC as determined by flow cytometry (Data represent mean ± SD of triplicates;  
n = 3). 
 
 
 
 
 
4.     Results!
_____________________________________________________________________ 
! +)!
 
 
Previously, several pteridin derivatives were reported to inhibit different 
protein kinases (Doukas et al., 2009; Gomtsyan et al., 2004; Leung et al., 
2006). Therefore, it was hypothesized that a kinase may be the target of TR. 
A kinase profiling assay against a selected panel of more than 100 protein 
kinases and their isoforms, covering the majority of the signaling pathways 
reported to govern stem cell fate was performed with TR (Appendix 1). 
According to this screen TR specifically inhibited casein Kinase 1$ (CK1$) 
and phosphatidylinositide 3-kinase class 2% (PI3KC2%). To validate CK1$ and 
PI3KC2% as possible targets of TR during ESC conversion I selected the pan-
PI3K inhibitor LY294002, the potent and selective PI3K gamma inhibitors AS-
605240 and TG100-115, and the CK1$/% inhibitor D4476. While inhibition of 
PI3K did not lead to induction of OCT4-GFP expression, using D4476 to 
inhibit CK1$/% resulted in a significant number of OCT4-GFP–positive cells 
(Figures 33 and 34). 
 
 
 
 
 
Figure 34. OCT4-GFP expression in EpiSC after 8 days treatment with the CK1 
inhibitor D4476 and the PI3K inhibitor TG100-115. 
(Scale bar: 300 µm). 
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Having identified CK1$ as a target of TR, Andrei Ursu then chemically 
synthesized a library of about 80 derivatives around the pteridine scaffold in 
an attempt to study the structure-activity-relationship for inhibition of CK1$, 
and to produce a more potent inhibitor that would further augment conversion 
(Ursu, 2014). I tested the synthesized compounds in an EpiSC conversion 
assay based on OCT4-GFP and PECAM1 expression as readout using 
FACS. The SAR study revealed that modifications of the phenyl ring in 
position 6 of the pteridine scaffold resulted in significant changes in compound 
activity. Interestingly, while any modifications in the para-position of the 
phenyl ring reduced compound activity dramatically, introducing substituents 
in the meta-position such as fluorine, chlorine, bromine, or methyl produced 
more active compounds with the chlorine derivative showing the highest 
conversion efficiency (Figures 35 and 36). Detailed information concerning the 
synthesis of the derivatives will be part of the doctoral dissertation of Andrei 
Ursu, and are not further discussed in this thesis (Ursu, 2014). 
 
 
 
 
 
 
Figure 35. Chemical structure of the Triamterene derivative AU52. 
(o: ortho, m: metha, p: para). 
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The potential of AU52 to convert EpiSC was assessed based on the induction 
of PECAM1 and OCT4-GFP upon treatment. AU52 clearly demonstrated the 
highest conversion efficiency among the selected inhibitors (Figure 36). It 
achieved a 3-fold higher conversion efficiency than 2i/LIF. Wnt inhibition alone 
did not yield PECAM1/OCT-GFP double-positive cells, and neither did sodium 
butyrate which was previously reported to be capable of ESC-conversion of 
EpiSC (Figure 36).  
 
 
 
 
 
 
Figure 36. Conversion efficiency of AU52 compared to other inhibitors. 
Percentage of OCT4-GFP and PECAM1 (CD31) double–positive cells after 7 days 
ESC conversion with AU52, TR, 2i, CH, NaB, and D4476 in EpiSC-GOF18 as 
measured by flow cytometry. 
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Consistently, the derivative AU52 which demonstrated the highest biological 
activity clearly showed stronger inhibition of CK1$, with IC50 values of  
7.95 µM for TR, and 5.79 µM for AU58 (Figure 37). The graph in figure 37 
was generated by Andrei Ursu. 
 
 
 
 
 
 
 
Figure 37. Dose-response curves of Triamterene and its derivative AU52 for the 
inhibition of CK1!. 
The IC50 values were calculated to be 7.95 µM for TR and 0.44 µM for AU52. 
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Having identified AU52 as the derivative with the highest conversion efficiency 
and a nearly 20 times higher affinity for CK1$ than TR, the selectivity of AU52 
and TR among the selected panel of kinases, particularly among the CK 
family members, were then assessed (Figure 38 and Appendix 1). AU52 
displayed a selectivity very similar to that of TR (Appendix 1). Although TR 
and AU52 both displayed stronger inhibition of CK1$, they also inhibited 
CK1%, suggesting a potential role also for CK1% in ESC conversion (Figure 
38).  
 
 
 
 
 
 
Figure 38. Kinase acitivity profiling of Triamterene against representatives of 
the casein kinase family. 
(Compound concentration = 10 µM; data represent mean ± SD of triplicates; n = 3). 
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The IC50 values against CK1% were calculated to be 23.65 µM for TR and  
5.36 µM for AU52 (Figure 39). The graph in figure 39 was generated by 
Andrei Ursu. 
 
 
 
 
 
 
 
Figure 39. Dose-response curves of Triamterene and its derivative AU52 for the 
inhibition of CK1". 
The IC50 values were calculated to be 23.65 µM for TR and 5.36 µM for AU52. 
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Next, the ability of AU52 to promote the reversion of EpiSC was analyzed in 
further detail. Among a set of different compounds AU52 displayed the 
highest conversion efficiency based on OCT4-GFP and PECAM1 reactivation, 
almost 2-fold higher than TR and 3-fold higher than 2i (Figure 36).  
Interestingly, CH, as well as sodium butyrate, had a negliagible effect on the 
reactivation of OCT4-GFP and PECAM1 (Figure 36). AU52-converted cells 
exhibited cell morphology, OCT4-GFP expression, AP immunoreactivity, 
protein levels of Sox2, Nanog and Stella, and gene expression profile similar 
to those of ESC (Figure 40). Immunocytochemical characterization of AU52-
converted cells was performed by Dr Miao Zhang. 
 
 
 
 
 
 
 
Figure 40. Characterization of AU52-converted cells. 
Left panel) Morphology, OCT4-GFP and ALP expression in AU52-GOF18 cells 
(Scale bars: 300 µm). Middle panel) Immunofluorescence analysis for SOX2, 
NANOG, and STELLA (DPPA3) in AU52-GOF18 cells. DAPI was used for nuclear 
staining (Scale bar: 300 µm). Right panel) Comparison of gene expression patterns 
in ESC, AU52-GOF18 cells, and EpiSC. Expression levels are normalized to those of 
EpiSC (Data represent mean ± SD of triplicates; n = 3). 
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Most importantly, AU52-converted cells regained the ability to contribute to 
chimeras when injected into blastocysts (Figure 41). The chimeric mice were 
generated by Dr Guangming Wu by morula aggregation. 
 
 
 
 
 
 
 
Figure 41. Chimeric mice derived from AU52-GOF18 cells upon blastocyst 
injection. 
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4.7 CK1!/" Inhibition Promotes the Activation/Maintenance of the 
ESC Pluripotency Gene Regulatory Network   
 
Then, it was analysed how CK1$/% inhibiton influenced the expression of 
known pluripotency factors in EpiSC after treatment with TR for 2, 4, 6, and 8 
days. Notably, Klf2, Nanog, and Esrrb were upregulated from day2, albeit with 
different expression dynamics (Figure 42).  
 
 
 
 
 
Figure 42. Timecourse for whole mRNA expression of Klf2, Nanog, and Esrrb in 
Triamterene-treated EpiSC. 
Gene expression levels were normalized to those of untreated EpiSC samples (Data 
represent mean ± SD of triplicates; n = 3). 
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In the case of Nanog and Esrrb, the expression levels following 8 days of 
treatment with TR exceded those in ESC. This result was recapitulated using 
D4476, another inhibitor of CK1$/% (Figure 43). 
 
 
 
 
 
Figure 43. RT-qPCR analysis of TR-induced expression of Nanog and Esrrb. 
Untreated EpiSC, ESC and EpiSC treated for 8 days with TR (upper panel), and 
D4476 (lower panel). Gene expression levels were normalized to those of untreated 
EpiSC samples (Data represent mean ± SD of triplicates; n = 3). 
 
 
Then, the role of Klf2, Nanog, and Esrrb during AU52-based conversion was 
determined by shRNA-based knockdown (KD) experiments (Figure 44). 
Interestingly, Nanog-KD basically abolished conversion by AU52, and Klf2-KD 
significantly reduced the conversion, suggesting critical roles for both factors 
in the process. Esrrb-KD was less dramatic, but still reduced the conversion  
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efficiency of AU52 by about 30% (Figure 44). Transduction of shRNA was 
performed by Dr Kee Pyo Kim. 
 
 
 
Figure 44. Knockdown of Esrrb, Nanog, and Klf2 in EpiSC during ESC 
conversion with AU52. 
Upper panel) Percentage of OCT4-GFP and PECAM1 (CD31) double–positive cells 
after 6 days treatment with AU52 together with shRNA-based knock down of Esrrb, 
Nanog, and Klf2 respectively, in EpiSC-GOF18 as measured by flow cytometry. 
Lower panel) Assessment of shRNA-based knock down efficiency by RT-qPCR 
analysis (Data represent mean ± SD of triplicates; n = 3). 
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Based on the effect of CK1$/% inhibitors on key pluripotency genes during the 
reversion of EpiSC to ESC-like cells, it was tested whether TR/AU52 had an 
effect on self-renewal by maintaining the pluripotency gene regulatory 
network. Too high levels of AU52 are toxic (data not shown). N2B27 medium 
alone is not permissible for ESC self-renewal. However, following a titration 
experiment an optimal working concentration of 2 µM AU52 in ESC was found 
at which the clonal expansion of ESC in N2B27 was promoted. Addition of 
either LIF or PD to AU52-supplemented media increased the self-renewal 
ability of the cells, whereas addition of CH to AU52-supplemented media 
decreased their self-renewal (Figure 45). Clonal assays were performed by Dr 
Rodrigo Osorno. 
 
 
 
 
 
Figure 45. Clonal assay of ESC in the indicated culture conditions. 
ESC were plated onto gelatin coated plates and cultured for 7 days, after which the 
cells were stained for alkaline phosphatase and counted. (F: FCS, L: LIF, 52: AU52) 
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Upon switch to EpiSC media (based on N2B27/ActivinA/bFGF), ESC acquire 
properties of primed pluripotency (Guo et al., 2009). Nanog-GFP ESC show 
progressive downregulation of Nanog-GFP under this condition (Chambers et 
al., 2007; Karwacki-Neisius et al., 2013). Wnt signaling has been reported to 
prevent the commitment of ESC into EpiSC (ten Berge et al., 2011). 
Consistent with this finding, it was found that downregulation of Nanog-GFP 
during EpiSC differentiation was blocked by the addition of TR with an 
efficiancy comparable to the Wnt agonist CH (Figure 46). The assay of figure 
46 was performed by Dr Rodrigo Osorno. 
 
 
 
Figure 46. Differentiation of ESC into EpiSC is blocked by supplementation of 
TR. 
Flow cytometry analysis of Nanog-GFP positive cells during EpiSC differentiation 
(A/F) and in the presence of either Chiron or TR. (A: ActivinA, F: bFGF, black cell 
population represents non-fluorescent control cells). 
 
4.     Results!
_____________________________________________________________________ 
! ,,!
 
 
On the other hand, it has been shown that ESC cultured in the presence of 
serum and LIF result in transcription factor heterogeneity, coinciding with the 
presence of cells with different self-renewal capabilities (Chambers et al., 
2007). To test the ability of TR/AU52 to maintain homogenous expression of 
ICM transcription factors, two reporter lines were used, Nanog-GFP and 
Esrrb-Tomato. TR treatment induced high, homogenous expression of Nanog-
GFP and Esrrb-Tomato for the duration of the assay, whereas untreated 
controls gave rise to Nanog-GFP-negative and Esrrb-Tomato-negative cells 
(Figure 47). The heterogeneity assays of figure 47 using Nanog-GFP and 
Esrrb-Tomato reporter ESC were performed by Dr Rodrigo Osorno. 
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Figure 47. Heterogeneity of Nanog-GFP and Esrrb-Tomato is blocked by the 
presence of Triamterene. 
Flow cytometry analysis of Nanog-GFP (left) and Esrrb-Tomato (right) reporter ESC 
cultured in GMEM!/FCS/LIF/TR at low density for the indicated days (black cell 
population represents non-fluorescent control cells). 
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4.8 Inhibition of CK1" Results in Simultaneous Activation of WNT 
Signaling and Inhibition of TGF#/SMAD2 Signaling 
 
Next, the mechanism by which inhibition of CK1$/% exerts its effects was 
investigated. Signaling pathways known to be involved in ESC pluripotency 
were analyzed upon treatment with CK1 inhibitors. It was found that AU52 
prevented phosphorylation of !-CATENIN as well as SMAD2 (Figure 48). It 
also affected STAT3 phophorylation which is probably a result of the inhibition 
of PI3K which was identified by kinase profiling. In contrast, the ERK pathway 
was not affected (Figure 48). The western blot analysis was performed by Dr 
Juyong Yoon. 
 
 
 
Figure 48. Western blot analysis showing the effects of AU52 and Chiron on  
#-CATENIN, SMAD2, STAT3, and ERK phosphorylation in EpiSC. 
Cells were treated with either AU52 or Chiron for 30min. 
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Following the inhibition of phosphorylation of !-CATENIN the effect of 
TR/AU52 on the WNT pathway were further analyzed. To determine the 
enrichment of factors associated with signaling pathways, a gene ontology 
enrichment analysis was performed with the genes that were significantly 
upregulated within 12 hours of TR treatment of EpiSC. Based on this analysis 
the WNT receptor signaling pathway clearly ranked at the top of significantly 
enriched "biological process" terms (Figure 49). The bioinformatics analysis of 
microarray data was performed by Dr Marcos Jesus Arauzo Bravo. 
 
 
 
 
 
 
Figure 49. Direct acyclic graph (DAG) associated with the top 3 significantly 
enriched gene ontology terms. 
The higher the significance of the term, the more red is the box framing the term. The 
significantly enriched terms are encircled by ellipses. The most significant term 
shown is Wnt receptor signaling pathway with the p-value of 8.3683e-8. 
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The known WNT/Tcf target genes Axin2, Cdx1, and T-brachyury were 
upregulated upon TR treatment (Figure 50) (Kelly et al., 2011).  
 
 
 
 
 
 
 
Figure 50. RT-qPCR analysis of the expression of WNT target genes in EpiSC 
upon treatment with Triamterene. 
The gene expression levels are normalized to those of untreated samples. 
CHIR99021 and XAV939 were used as a positive and negative control, respectively 
(Data represent mean ± SD of triplicates; n = 3). 
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Then, I performed the TOPFlash Tcf-Luciferase assay to assess the WNT-
inducing activity of AU52, and found that AU52 was more active than CH 
(Figure 51).  
 
 
 
 
 
Figure 51. Luciferase assay of Tcf/Lef-mediated transcriptional activity in 
EpiSC as a result of AU52 and Chiron treatment. 
Chiron was applied as a positive control. Columns depict TOP/FOP ratio (Data 
represent mean ± SD of triplicates; n = 3; p < 0.001). 
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Then, it was tested whether the positive effect on ESC self-renewal that was 
observed upon AU52 treatment depended on the Wnt/!-CATENIN pathway 
(Figure 45). To this end, an ESC line in which both  
!-catenin alleles have been floxed and that also carries a CreERT2 cassette 
inserted into the ROSA26 locus (Bcateninfl/fl) was used (Brault et al., 2001; 
Tsakiridis et al., 2014). Treatment of Bcateninfl/fl ESC by 4-Hydroxytamoxifen 
induces deletion of both !-catenin alleles generating Bcatenin-/- ESC. 
Bcatenin-/- ESC are unable to self-renew in the presence of CH/PD (2i) or 
CH/LIF. In the absence of !-catenin, self-renewal is only supported by the 
combined presence of PD and LIF, though greatly diminished (Wray et al., 
2011). Interestingly, though equally diminished by depletion of !-catenin, 
AU52 still mediated ESC self-renewal (Figure 52). Clonal assays were 
performed by Dr Rodrigo Osorno. 
 
 
 
 
Figure 52. Clonal assay of Bcateninfl/fl and Bcatenin-/- ESC in the indicated 
culture conditions. 
Bcateninfl/fl ESC were plated at clonal density (600 cells) onto gelatin coated plates 
and cultured for 7 days, after which the cells were stained for alkaline phosphatase 
and counted. In order to generate Bcatenin-/-, Bcateninfl/fl were plated just as 
described above. After 48hrs the cells were treated with 1 µM of 4-Hydroxytamoxifen 
for 24hrs to induce the Cre-excision of the floxed-Bcatenin. (P: PD, C: CH, L: LIF,  
52: AU52). 
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Finally, the potential of TR/AU52 to modulate the WNT pathway in vivo was 
assessed. Zebrafish embryos from 7-48 hpf were kept in the presence of TR 
or AU52. At 48hpf the zebrafish embryos showed a typical phenotype that 
results from WNT over-activation during this period of development, including 
an impaired development of the eyes, the forehead, and the tail (Figure 53). 
The zebrafish assay was performed by Kathrin Grassme. 
 
 
 
Figure 53. Phenotypes of zebrafish embryos at 48hpf. 
The embryos were allowed to grow in the presence of the indicated inhibitors from 
7hpf (hpf: hours post fertilization, scale bar: 500 µm). 
 
SMAD2 was affected by TR/AU52 (Figure 48). Therefore, I determined the 
role of SMAD2 during conversion. I hypothesized that TR/AU52 acted via dual 
inhibition of phosphorylation of both !-CATENIN and SMAD2 and thus 
simulated this action by applying CH together with SB in order to convert 
EpiSC. Interestingly, while CH and SB alone had rather differentiating effects 
on EpiSC, together they gave rise to ESC-like colonies expressing OCT4-
GFP and ICM marker genes comparable to ESC (Figure 54). Just like with 
TR/AU52 the conversion with CH/SB took six days and was accomplished 
under EpiSC culture conditions.  
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Figure 54. SB/CH-converted EpiSC. 
Upper panel) Morphology and OCT4-GFP expression in EpiSC treated for 6 days 
with the indicated inhibitors (Scale bar: 200 µm). Lower panel) RT-qPCR analysis of 
ICM marker gene expression in SB/CH-treated cells, EpiSC and ESC. Gene 
expression levels were normalized to those of untreated EpiSC samples (Data 
represent mean ± SD of triplicates; n = 3). 
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A role for CK1$/% in !-catenin and Smad2 phosphorylation was previously 
reported (Amit et al., 2002; Waddell et al., 2004). To determine whether 
CK1$/% was involved in !-catenin and Smad2 phosphorylation, an shRNA-
based KD of CK1$ and CK1% in EpiSC was performed. Most strikingly, KD of 
CK1%, and not CK1$, gave rise to OCT4-GFP-positive cells, and Western blot 
analysis revealed that KD of CK1% hindered phophorylation of both !-catenin 
and Smad2 (Figure 55). Given the fact that TR did not inhibit GSK3! and ALK 
(Appendix 1), these findings suggest that TR/AU52 acts on !-catenin and 
Smad2 phosphorylation via CK1%. Transduction of shRNA was performed by 
Dr Kee Pyo Kim. Western blot analysis was performed by Dr Juyong Yoon. 
 
 
 
 
 
Figure 55. Knockdown of CK1!  and CK1"  in EpiSC. 
Left panel) Assessment of shRNA-based knock down efficiency by RT-qPCR 
analysis (above, data represent mean ± SD of triplicates; n = 3) and  
OCT4-GFP expression in EpiSC-GOF18 after shRNA-based knock down of CK1" 
(below, scale bar: 250 µm). Right panel) Western blot analysis of  
!-catenin and Smad2 phosphorylation in EpiSC after shRNA-based knock down of 
CK1!  and CK1" . 
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Finally, the role of LIF during the conversion was left to be clarified. TR was 
found to inhibit PI3K which could explain the blocked Stat3 phophorylation 
pointing toward a redundancy of this pathway during conversion (Figure 48 
and Appendix 1). Moreover, ESC could be maintained with AU52 alone, i.e. 
without LIF, for an extended period, and SB/CH could equally maintain ESC 
without LIF (Figure 56).  
 
 
 
 
 
Figure 56. Morphology and OCT4-GFP expression in ESC cultured for 8d under 
the indicated conditions. 
(Scale bar: 100 µm). 
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To categorically determine whether LIF/Stat3 signaling is involved in AU52-
mediated self-renewal Stat3-/- ESC were used. These ESC can only be 
propagated by the supplementation of CH/PD (2i) (Ying et al., 2008).  In the 
absence of Stat3, AU52-mediated self-renewal was severely reduced in the 
presence of either LIF or CH (Figure 57). In contrast, the dual inhibition of Erk 
and CK1 (N2B27/PD/AU52), promoted a robust propagation of Stat3-/- ESC 
for more than two months (Figure 57). Clonal assay was performed by Dr 
Rodrigo Osorno. 
 
 
 
 
Figure 57. Colony formation of Stat3-/- ESC after clonal density plating and 7 
days culture under the indicated conditions. 
(P: PD, C: CH, L: LIF, 52: AU52). 
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Stat3-/- ESC cultured for more than two months in PD/AU52 retain robust 
expression of OCT4, NANOG, ESRRB and KLF4 proteins, and give rise to 
chimeric mice upon blastocyst injection (Figures 58). Immunocytochemical 
characterization was performed by Dr Rodrigo Osorno. 
 
 
 
 
 
 
 
Figure 58. Stat3-/- ESC maintained in AU52/PD exhibit chimera-grade 
pluripotency. 
Left panel) Immunofluorescence analysis of Oct4, Nanog, Esrrb, and Klf4 in Stat3-/- 
ESC cultured for two months in the presence of PD/AU52 (Scale bar: 200 µm). Right 
panel) Chimeric mice derived from the injection of Stat3-/- MF1 ESC into BL6 
blastocyst. Prior to blastocyst injection the  
Stat3-/- ESC were cultured for two months in the presence of PD/AU52. 
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Taken together, the data of this thesis suggest a concise mechanism of action 
for TR/AU52 that is based on !-catenin and Smad2 modulation via inhibition 
of CK1% (Figure 59).     
 
 
 
 
 
 
 
Figure 59. Schematic model of the mechanism through which TR/AU52 reverts 
recalcitrant EpiSC into ESC pluripotency. 
See text for discussion. 
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5. Discussion 
 
 
5.1 Recalcitrant Late-Stage EpiSC 
 
It has been shown that EpiSC are heterogeneous within a given cell line, and 
to different degrees among cell lines (Bao et al., 2009; Bernemann et al., 
2011; Han et al., 2010; Tsakiridis et al., 2014). Only a small subpopulation of 
EpiSC displays features of the early post-implantation epiblast (Bao et al., 
2009; Han et al., 2010), whereas the vast majority of EpiSC functionally 
represent late stages of the postimplantation epiblast. Early-stage EpiSC are 
susceptible to media-induced reversion to an ESC-like state, whereas late-
stage EpiSC are refractory to this process (Figures 4, 5) (Bernemann et al., 
2011; Han et al., 2010). In this study, using a small-molecule library screen, I 
found a novel compound able to induce the conversion of early- and late-
stage EpiSC into ESC-like cells, and I describe how this is accomplished. To 
my knowledge this is the first study showing the robust conversion of 
recalcitrant late-stage EpiSC to ESC through chemical means alone.  
The starting point for this project was the wide acceptance of an 
unsubstantiated notion within scientists studying naïve and primed 
pluripotency that basically all EpiSC can be reverted into naïve pluripotent 
cells with the current protocols. In particular, the misconception lies in the 
assumption that the methods by which naïve pluripotency can be induced 
actually apply to all EpiSC. In stark contrast to this assumption, the most 
widely accepted conversion method based on culture conditions, namely the 
presence of 2i/LIF in the culture medium, is far from being a universal 
conversion method for EpiSC. Inhibition of MEK and GSK3#, together with the 
presence of LIF, can convert only a select fraction of EpiSC (Figures 1, 4) -  
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a specific fraction that demonstrates features of naïve pluripotency such as 
ICM integration and chimeric competence (Han et al., 2010).  
 
 
5.2 Small Molecule Screening Assay 
 
Following a chemical genetic approach I developed a small molecule 
screening assay to identify ligands capable of converting recalcitrant late-
stage EpiSC into naïve pluripotency. By identifying the protein targets of such 
ligands I tried to define the mechanism governing conversion of late-stage 
EpiSC to a naïve pluripotent state. I screened the LOPAC library of known 
pharmacologically active compounds. The advantages of the LOPAC library 
are the cell penetrating capacity of the screened compounds, the broad range 
of target classes that are covered, and the known biological activity of the 
inhibitors. At the same time the known biological activity of the compounds 
promised to facilitate later target identification efforts.  
I developed a screening assay based on fluorescent reporter gene expression 
under the control of Oct4. Two Oct4 reporter lines were available: the OG2 
and GOF18 (E3) cell lines. EpiSC-GOF18 contain a GFP transgene under the 
control of the entire regulatory region of the Oct4 gene (Yeom et al., 1996). In 
EpiSC-OG2 the GFP reporter is solely under the control of the distal enhancer 
(DE) of the Oct4 gene, i.e. the construct lacks the proximal enhancer (Oct4-
$PE-GFP) (Yeom et al., 1996). The distal enhancer of Oct4 contains a dense 
binding locus for key ESC-specific transcription factors (Chen et al., 2008). 
The fact that EpiSC preferentially utilize the PE over the DE, and that the 
Oct4-$PE-GFP is only active in ESC and not in EpiSC suggests that EpiSC 
must be lacking some of the key ESC-specific transcription factors (Tesar et 
al., 2007; Yeom et al., 1996). Accordingly, under their respective normal 
culture condition ESC (OG2) exhibit strong OCT4-GFP expression whereas 
OG2-EpiSC do not express OCT4-GFP (Figure 1). Theoretically, EpiSC-
GOF18 containing both the PE and the DE should be OCT4-GFP positive.  
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However, only a very low percentage of established EpiSC-GOF18 expresses 
OCT4-GFP which probably results from epigenetic modifications during the 
adaptation to the in vitro culture conditions affecting the Oct4-GFP transgene, 
but not the endogenous Oct4 (Figures 1, 3). I made use of the differential 
expression of the OCT4-GFP reporter in EpiSC and ESC to detect converted 
cells in the screening assay and hence active compounds. 
I chose to keep the EpiSC in CM and not in mESC medium supplemented 
with LIF that is used for the conversion with 2i. This EpiSC culture condition 
was more stringent in two ways: Through the absence of additional LIF 
spontaneous conversion was prevented, and the presence of FGF2 
represented an additional "barrier" toward naïve pluripotency. Thus, I was 
able to design an assay with a satisfactory screening window (Figures 8, 9). 
Once a hit compound had been identified, the converted cells needed to be 
extensively characterized as authentic naïve pluripotent stem cells. A high-
content imager was used for the readout to identify converted naïve stem 
cells. Dissociation into single cells prior to the readout allowed me not only to 
detect cells with a GFP intensity equal to ESC, but also to quantify them. 
Hence, the readout was based on the number of single cells with a GFP 
intensity equivalent to those in ESC.  
 
 
5.3 Triamterene 
 
Our screening assay yielded a pteridine derivative known as Triamterene 
(Figures 10, 11), which blocks the epithelial sodium channel (ENaC), and is 
clinically used as a diuretic (Busch et al., 1996). The fact that despite the 
small library size Triamterene turned out as a hit that could subsequently be 
validated in secondary assays was a great surprise.  
The screen was initially performed with unsorted EpiSC-GOF18. The next 
step after identifiying Triamterene was to confirm its activity on late-stage 
EpiSC. Triamterene induced transgenic Oct4-GFP expression in recalcitrant  
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EpiSC of both the EpiSC-GOF18 and EpiSC-OG2 lines (Figure 12). The TR-
treated EpiSC changed their morphology toward smaller dome-shaped 
colonies. This newly acquired dome-shaped morphology could not be retained 
if cultured under EpiSC conditions, indicating that they had been converted to 
a state different to that of EpiSC (Figures 13-15). Furthermore, the activity of 
TR could be shown also for two other late-stage EpiSC lines, T9 and C1a1, 
through expression of the ESC-specific markers PECAM1, KLF4, and ESRRB 
(Figure 18) (Bernemann et al., 2011). The conversion was done in EpiSC 
medium, i.e. CM without addition of LIF. It is remarkable that Triamterene 
could induce the reversion of late-stage EpiSC despite the presence of FGF2 
which is known to prime ESC for differentiation (Burdon et al., 1999; Kunath et 
al., 2007; Stavridis et al., 2007). Gene expression analyses by qRT-PCR 
revealed that other ESC specific markers were upregulated, such as Nanog, 
Rex1, Stella, Dppa4, and Dppa5 (Figure 16). Consistently, early lineage 
markers like Fgf5, Fgf8, and T were downregulated. An overall assimilation of 
the global gene expression pattern toward that of ESC could be observed 
(Figure 17).  
The TR-induced conversion of EpiSC from primed to naïve pluripotency 
displays several striking features distinct from the 2i-based conversion. After a 
relatively short exposure period to induce naïve pluripotency (6-8 days), TR-
converted cells could be clonally expanded and maintained in LIF-
supplemented ESC medium - without further addition of TR. Notably, TR 
induces the expression of OCT4-GFP in EpiSC cultured in CM medium 
despite the presence of FGF2 and without added LIF. This is likely to be 
possible as MEF-conditioned medium contains LIF. However, it was found 
that TR also inhibits PI3K-mediated STAT3 phosphorylation indicating a 
redundency of this pathway during the conversion (Figure 48). Furthermore, 
STAT3-null ESC could be stably maintained and expanded in AU52/PD, or 
TR/PD, and even maintained the capacity to give rise to chimeric mice 
(Figures 57, 58).   
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Despite the apparent assimilations toward the naïve pluripotent state cells 
derived with TR alone failed to contribute to chimerism. The lack of 
homogenous high expression of OCT4-GFP in all TR-derived cells already 
raised suspicion whether the cells were fully converted (Figure 13). Global 
gene expression analysis then indeed pointed out that gene expression was 
not identical to that of ESC (Figure 17, 27). I do not want to exclude that 
chimera competent cells can be derived from recalcitrant EpiSC through the 
conversion with TR alone. Maybe the presence of FGF2 during the 
conversion, which is known to prime ESC for differentiation, counteracts the 
effect of TR (Burdon et al., 1999; Kunath et al., 2007; Stavridis et al., 2007). I 
was also able to convert late-stage EpiSC in N2B27-based ESC medium and 
in KO-DMEM-based ESC medium in the absense of FGF2. Proper selection 
of cell colonies with high OCT4-GFP expression and repeated subcloning 
might yield homogenous strongly OCT4-GFP-expressing cells capable of 
chimera contribution. Another important issue in this context is the passage 
number of the late-stage EpiSC before conversion. It could be that cells of an 
earlier passage revert more readily to cells that can contribute to chimeras. 
 
 
5.4 FGF/ERK Inhibition 
 
Activation of the FGF/ERK pathway predisposes ESC to undergo 
differentiation (Burdon et al., 1999; Kunath et al., 2007; Stavridis et al., 2007).  
In contrast, ERK-inhibition in combination with LIF and/or CH supports the 
maintenance of undifferentiated ESC (Ying et al., 2008). The presence of 
FGF2 in the EpiSC culture medium that was used for the conversion might 
have been a hindering factor toward full reprogramming. This is why I tried to 
complete conversion by inhibition of the FGF/ERK pathway. Inhibition of this 
pathway in TR-converted cells facilitated the transition of these cells to naïve 
pluripotency (Figures 20-32). ERK inhibition lead to strong downregulation of 
many lineage markers including Fgf5 and Fgf8, and simultaneous  
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upregulation of ESC-specific marker genes like Klf4, Tbx3, and Tcl1 (Figure 
29). An overall assimilation to the ESC-like state was observed including 
changes in the epigenetic markup and Oct4 promoter utilization (Figures 24, 
30). Most importantly TR/PD-converted cells resulted in chimera competent 
cells capable of germline contribution (Figure 32). It is important to state that 
ERK inhibition merely completes TR-induced conversion. TR/PD-based ESC 
conversion is a two-step procedure that is initiated by TR and completed by 
Erk inhibition. Neither does ERK inhibition alone induce naïve pluripotency 
even in early-stage EpiSC (Figure 54), nor is it necessary at the beginning of 
the TR-induced conversion (Figures 12, 18). Even the combined inhibition of 
ERK and GSK3# (2i) does not suffice to convert late-stage EpiSC (Figures 4, 
5). As discussed earlier I cannot exclude that under certain favourable 
conditions chimera competent ESC-like cells can be derived from late-stage 
EpiSC through the conversion with TR alone. As ERK inhibition merely 
completes the conversion of recalcitrant EpiSC to naïve pluripotent cells, I 
consider it straightforward to hypothesize that for the most part conversion 
can be attributed to the effects of TR. 
 
 
5.5 Casein Kinase 1"  (CK1") 
 
Pteridin derivatives were known to inhibit protein kinases (Doukas et al., 2009; 
Gomtsyan et al., 2004; Leung et al., 2006). It was, therefore, hypothesized 
that a kinase may be the target of TR, and TR was profiled against a set of 
selected protein kinases which were previously reported to be relevant in 
stem cell biology.  
Several kinase inhibitors were reported to support induced pluripotent stem 
(iPS) cell generation, or to promote ground-state pluripotency (Ichida et al., 
2009; Li and Rana, 2012; Maherali and Hochedlinger, 2009; Sato et al., 2004; 
Ying et al., 2008). I tested TR against the reported kinases, but none were 
affected by TR (Appendix 1). Notably, TR did not inhibit GSK3!, MEK/ERK  
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nor ALK4/5, which are all known targets that promote the reversion of EpiSC 
to ESC-like cells (Greber et al., 2010; Zhou et al., 2010) (Appendix 1). This 
observation suggested that TR might be working through the regulation a 
different kinase. 
Kinase profiling revealed that TR inhibited CK1$/% and PI3KC2# (Appendix 1). 
Notably, however, none of the PI3K inhibitors tested were able to induce 
OCT4-GFP expression in EpiSC (Figures 33, 34). Therefore, I excluded PI3K 
as the effective target of TR-induced reversion of EpiSC. In contrast, a 
structurally unrelated CK1$/% inhibitor (D4476) was able to induce OCT4-
GFP, and promote Nanog and Esrrb expression in EpiSC (Figures 33, 34, 36, 
43). Profiling of TR against different isoforms of the Casein kinase family 
revealed affinity to CK1! and CK1" (Figure 38). This is not surprising given 
the highly conserved protein sequences of these two isoforms. The IC50 
values were 7.95 µM and 23.65 µM for CK1! and CK1", respectively (Figures 
37, 39). Importantly, knockdown of CK1% (and not knockdown of CK1$) gave 
rise to OCT4-GFP positive colonies, and resulted in a reduction of  
!-CATENIN and SMAD2 phosphorylation, thus, further substantiating the role 
for CK1% in the reprogramming process (Figure 55).  
Taken together, I report the first chemical conversion of late-stage EpiSC to 
the naïve pluripotent state and also define for the first time a role for CK1% in 
this process.  
 
 
5.6 AU52 
 
In collaboration with Andrei Ursu, who synthesized the Triamterene 
derivatives, I performed a structure-activity-relationship analysis with TR with 
the aim to study the structural requirements needed for naïve conversion. 
Detailed information concerning the synthesis of the Triamterene derivatives 
will be part of Andrei Ursu's dissertation and will not be discussed here (Ursu, 
2014). The aim of the SAR study was to explore potential room for synthetic  
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improvement of activity and to detect the indispensable substituents with 
regard to the design of pulldown probes for follow-up studies. The phenyl ring 
in position 6 of the pteridine scaffold proved to be sensitive to synthetic 
modifications with regard to the compound's conversion efficiency. The para-
position of the phenyl ring was particularly sensitive, as insertions of any 
substituents resulted in a dramatic decrease of compound activity. Introducing 
substituents in the meta-position, on the other hand, such as fluorine, 
chlorine, bromine, or methyl, resulted in more active compounds with the 
chlorine derivative showing the highest conversion efficiency (AU52, Figure 
35). Consistently, the higher biological activity was accompanied by obviously 
stronger inhibition of CK1$ and CK1% with IC50 values of 0.44 µM and 5.36 
µM, respectively (Figures 37, 39). AU52 showed a kinase inhibition profile 
similar to TR and was subsequently used as a substitute for TR. I could show 
that AU52 was capable of converting late-stage EpiSC into ESC-like cells 
sharing the features of naïve pluripotency (Figure 40). Most importantly, AU52 
converted cells contributed to chimeric mice (Figure 41). 
 
 
5.7 WNT and TGF# Signaling 
 
CK1 family members are known to exert both negative and positive effects on 
WNT signaling (Price, 2006). Potential contact points for negative regulation 
of WNT signaling via phosphorylation by CK1 include !-CATENIN (Amit et al., 
2002; Liu et al., 2002), APC (Rubinfeld et al., 2001), and LRP5/6 (Swiatek et 
al., 2006). However, members of the CK1 family are also known to be 
involved in numerous other processes including p53 and E-CADHERIN 
modifications, nuclear-cytoplasmic shuttling of transcription factors and  TGF! 
signaling (Dupre-Crochet et al., 2007; Knippschild et al., 1997; Rena et al., 
2004; Waddell et al., 2004). The agonistic effect of TR/AU52 on the WNT 
pathway was confirmed in vitro (Figures 48-52) and in vivo (Figures 53).  
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However, the finding that TR/AU52 simultaneously modulate  
WNT/!-CATENIN and TGF!/SMAD2 signaling via inhibition of CK1% is of 
special importance. By this I show that only activation of the WNT pathway 
together with the simultaneous inhibition of SMAD2 signaling can reproduce 
the TR/AU52-based reprogramming.,which is in contrast to affecting the 
individual pathway (Figures 48, 54, 55). This finding helps us to understand 
why neither SB, nor CH alone can convert EpiSC to a naïve pluripotent state. 
Neither the CK1% pathway nor the TGF!/SMAD2 pathway to date were known 
to be involved in naïve conversion of late-stage EpiSC. Thus, I also 
demonstrate why WNT modulation alone, or even 2i/LIF is incompetent in this 
regard. The missing link in 2i/LIF-based conversion indeed is inhibition of 
TGF!/SMAD2 signaling.  
 
 
5.8 Klf2, Nanog, and Esrrb 
 
TR-treatment of EpiSC coincided with strong upregulation of the key ESC-
specific pluripotency markers Klf2, Nanog and Esrrb (Figures 42, 43). 
Interestingly, KD of Klf2 or Nanog significantly impaired TR/AU52-based 
conversion, highlighting their importance during this process (Figure 44). 
Esrrb-KD reduced by half the number of AU52-induced OCT4-GFP-positive 
cells (Figure 44). However, it should be noted that the shRNA probes for 
Esrrb were less efficient than those for Nanog and Klf2 (Figure 44). In any 
case, these three factors may indeed be necessary in the chemical-induced 
reversion of EpiSC, which is consistent with previous reports that they 
promote the efficient conversion when expressed in EpiSC (Festuccia et al., 
2012; Hall et al., 2009; Silva et al., 2009).  
)aken together, I have developed a simple and efficient method for the 
conversion of recalcitrant EpiSC into an ESC-like state. The here presented 
findings reveal novel insights into the mechanisms governing the transition 
between primed and naïve pluripotency. Notably, I introduce CK1% as a key  
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player in the regulation of naïve pluripotency, through the direct modulation of  
WNT/!-CATENIN and TGF!/SMAD2 signaling which results in induction of 
the ESC-specific transcription factors Klf2, Nanog and Esrrb that drive the 
necessary change in the gene expression pattern of late-stage EpiSC.  
 
 
5.9 Summary 
 
EpiSC contain subpopulations within a given cell line, and to different degrees 
among cell lines. These subpopulations functionally correspond to an early 
and late stage of postimplantation development (Figure 59). Interestingly, the 
subpopulation, that normally is smaller in number and that represents early-
stage EpiSC, was found to contribute to chimeras when injected into the ICM 
at the blastocyst stage, which is considered a hallmark feature of 
preimplantation pluripotent cells. So far, late-stage EpiSC which represent the 
vast majority of EpiSC and cannot contribute to chimera development when 
introduced into the ICM were recalcitrant to chemical reprogramming to naïve 
pluripotency.  
The aim of the presented study was to enable the reversion of recalcitrant 
late-stage EpiSC to a naïve pluripotent state and to elucidate the molecular 
mechanism underlying the reversion. The questions that I was interested in 
were: Can recalcitrant late-stage EpiSC be reverted to a naïve ESC-like state 
by chemical means alone, i.e. without genetically invasive methods? If so, 
which extrinsic factors can accomplish naïve conversion of late-stage EpiSC? 
What is the underlying mechanism that such extrinsic factor exerts? 
Following a chemical genetic approach I discovered Triamterene to be able to 
induce the conversion of late-stage EpiSC to naïve pluripotent cells (Figure 
59). An SAR study in collaboration with Andrei Ursu revealed AU52 as a more 
potent Triamterene derivative capable of converting late stage EpiSC to naive 
pluripotency (Ursu, 2014). The data of the presented thesis demonstrate that 
Triamterene acts via a dual mechanism through the inhibition of CK1% (Figure  
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59). The inhibition of CK1%, namely, results in simultaneous inhibition of  
!-CATENIN and SMAD2 phosphorylation which actuates WNT and 
attenuates TGF# signaling (Figure 59). The simultaneous modulation of the 
two signaling pathways results in the induction of the ESC-specific 
transcription factors Klf2, Nanog and Esrrb which eventually drive the 
conversion to naïve pluripotency (Figure 59).  
Following up on the findings of the presented work there are several 
interesting aspects to be investigated to gain better understanding of the 
mechanisms governing naïve pluripotency. I introduce for the first time CK1% 
as a new player in naïve pluripotency. It would be interesting to determine 
whether the role of CK1 in the regulation of naïve pluripotency is conserved 
across species. It must be noted, however, that the ESC-specific markers 
Klf2, Nanog and Esrrb which are induced by the inhibition of CK1% and which 
were shown to convert EpiSC to naïve pluripotency in the mouse system are 
already expressed in hESC.  
It has been demonstrate that inhibition of CK1% results in simultaneous 
modulation of !-CATENIN and SMAD2 phosphorylation directly associating 
SMAD2 signaling with late-stage EpiSC. Inhibition of SMAD2 together with 
ERK signaling was recently shown to promote ESC derivation from non-
permissive mouse strains (Hassani et al., 2014). BMP4 signaling can be 
augmented in these cells which might indicate a crosstalk between SMAD2 
and BMP4-directed SMAD1. 
Finally, the role of ERK inhibition has to be studied in more detail to determine 
whether chimera competent naïve pluripotent cells can be obtained through 
TR/AU52 treatment alone (Figure 59). As suggested earlier key to that might 
be proper selection of converted colonies, and conversion media free of FGF. 
In the same sense, it might be possible to identify the minimal key set of 
genes that establish and control chimera competence.  
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7. Abstract  
 
 
7.1 Background 
 
Embryonic stem cells (ESC) are derived from the inner cell mass (ICM) of 
preimplantation embryos. They are capable of contributing to the development 
of chimeric mice when injected back into the ICM. This particular ability is 
called naïve or ground state pluripotency. Epiblast stem cells (EpiSC) are 
derived from the epiblast of postimplantation embryos. While they equally 
represent pluripotent cells capable of teratoma formation they do not 
contribute to the development of chimeras when injected into the ICM. This 
somewhat restricted pluripotency of the slightly more advanced embryo was 
termed primed, i.e. ready for lineage commitment. EpiSC are heterogenous 
within and among cell lines. They were shown to comprise at least two 
subpopulations which are functionally equivalent to the early and late stage of 
postimplantation development. The small fraction representing the early stage 
is even chimera competent while the vast majority representing the late stage 
is not chimera competent. Until now these late-stage EpiSC could not be 
reprogrammed to naïve pluripotency through chemical inhibitors alone. In 
contrast to early-stage EpiSC, late-stage EpiSC were recalcitrant to the 2i/LIF 
condition which is widely known to stabilize the ground state of pluripotency 
based on GSK3# and MEK inhibition. 
 
 
7.2 Aim of the Study 
 
The aim of the presented study was to identify a novel chemical means for the 
conversion of recalcitrant late-stage EpiSC into naïve pluripotency.  
7.     Abstract!.............................................................................................!
! $&+!
 
 
Through the study of the mechanism-of-action of the discovered inhibitors I 
aimed at the elucidation of the mechanism governing the establishment of 
ground state pluripotency in late-stage EpiSC. 
 
 
7.3 Methods 
 
Toward this end, I applied a chemical genetic approach. I developed a small 
molecule screening assay and used the LOPAC library of known 
pharmacologically active compounds to discover a hit compound. The hit 
compound was validated in secondary assays through full characterization of 
the converted cells using FACS, qRT-PCR, global transcription analysis, 
immunocytochemistry, teratoma and chimera assays. Target identification 
efforts included kinase profiling, testing of structurally diverse inhibitors, 
microarray and gene ontology analyses, structure-activity-relationship 
analyses and IC50 value determinations. Further investigations of the 
mechanism-of-action and target validation involved biochemical assays like 
western blotting, genetic knockdown experiments, and in vivo phenotypic 
zebrafish assays.  
 
 
7.4 Results 
 
I developed a 96-well plate small molecule screening assay based on the 
differential expression of the OCT4-GFP reporter in EpiSC-GOF18 and ESC 
using a high-content imager. I discovered Triamterene (TR) as a hit 
compound, a known diuretic pteridine derivative. Validation of the hit 
compound revealed that TR was capable of converting several late-stage 
EpiSC lines into a state that shared many features with ESC. The converted 
cells, however, did not yield chimeric mice when injected in blastocysts. This 
imparity could be overcome through complementation of TR-induced  
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conversion by the simultaneous inhibition of ERK signaling to yield ESC-like 
cells with full chimera competence. Kinase profiling identified CK1!/" and 
PI3Kclass2% as potential targets of TR. Subsequent gene knockdown 
experiments confirmed the isoform CK1" as the target of TR-induced 
conversion, and structure-activity-relationship analysis lead to the synthesis of 
a significantly more potent inhibitor capable of naïve conversion, termed 
AU52. Biochemical analyses revealed that inhibition of CK1" resulted in 
simultaneous inhibition of #-CATENIN and SMAD2 phosphorylation. The 
concurrent stimulation of WNT and attenuation of TGF# signaling lead to the 
induction of the ESC-specific transcription factors Klf2, Nanog, and Esrrb 
which eventually effected the naïve conversion.      
 
 
7.5 Conclusion 
 
Taken together, the findings of this thesis represent the first chemical 
condition for the conversion of late-stage EpiSC to naïve pluripotency. I 
introduce CK1" as a novel player to affect the core regulatory network of 
ground state pluripotency and elucidate the mechanism-of-action of TR/AU52-
induced naïve conversion. Finally, I offer a novel chemical platform as a 
convenient tool for further investigations of the two states of naïve and primed 
pluripotency.     
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8. Zusammenfassung (German) 
 
 
8.1 Einleitung 
 
Embryonale Stammzellen (ES-Zellen) werden aus der inneren Zellmasse 
(IZM) von Präimplantationsembryonen gewonnen. Sie sind in der Lage, zur 
Entwicklung von chimärischen Mäusen beizutragen, wenn sie in die IZM 
zurücktransplantiert werden. Diese besondere Fähigkeit wird als naive 
Pluripotenz oder als der Grundzustand der Pluripotenz bezeichnet. Epiblast-
Stammzellen (EpiS-Zellen) werden aus dem Epiblasten von 
Postimplantationsembryonen gewonnen. Während sie ebenfalls pluripotente 
Stammzellen darstellen, die in der Lage sind, Teratomen zu generieren, 
tragen sie nicht zur Entwicklung von chimärischen Mäusen bei, wenn sie in 
die IZM zurücktransplantiert werden. Diese etwas beschränkte Pluripotenz 
des geringfügig weiter entwickelten Embryos wird "primed" Pluripotenz 
genannt, d.h. bereit für die Festlegung auf ein Keimblatt. EpiS-Zellen sind 
heterogen sowohl innerhalb von, als auch zwischen Zelllinien. Es wurde 
gezeigt, dass sie aus mindestens zwei Subpopulationen bestehen, die 
funktional der frühen bzw. der späten Postimplantationsentwicklung 
entsprechen. Der kleine Anteil, der das frühe Stadium repräsentiert, ist sogar 
fähig Chimären zu generieren, während der allergrößte Teil, der das späte 
Stadium repräsentiert, nicht zur Entwicklung von Chimären beitragen kann. 
Bis jetzt konnten diese EpiS-Zellen des späten Stadiums nicht, allein durch 
chemische Inhibitoren, in naive Pluripotenz reprogrammiert werden. Im 
Gegenteil zu EpiS-Zellen des frühen Stadiums widersetzten sich EpiS-Zellen 
des späten Stadiums der 2i/LIF-Bedingung, mit dem die Stabilisierung des 
Grundzustands der Pluripotenz durch Inhibition von GSK3# und MEK erreicht 
werden kann.    
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8.2 Ziel der vorliegenden Arbeit 
 
Ziel der vorliegenden Arbeit war, eine neue chemische Methode für die 
Konvertierung von inerten EpiS-Zellen des späten Stadiums in naive 
Pluripotenz zu identifizieren. Im Rahmen der Untersuchungen des 
Wirkmechanismus der entdeckten aktiven Verbindungen sollte der 
Mechanismus, der der Etablierung des Grundzustands der Pluripotenz in 
EpiS-Zellen des späten Stadiums zugrunde liegt, aufgeklärt werden. 
 
 
8.3 Methoden 
 
Zu diesem Zweck wählte ich einen chemisch-genetischen Ansatz. Ich 
entwickelte ein systematisches Testverfahren (screening assay) zur 
Identifizierung von niedermolekularen Verbindungen (small molecules) und 
benutzten die LOPAC-Bibliothek von bekannten pharmakologisch aktiven 
Verbindungen, um "Treffer" (hits) zu finden. Der Hit wurde in 
Sekundärtestverfahren durch vollständige Charakterisierung der konvertierten 
Zellen mittels FACS, qRT-PCR, globaler Genexpressionsanalyse, 
Immunozytochemie und Teratom- und Chimärentest validiert. 
Untersuchungen zur Zielidentifizierung umfassten Kinaseprofilierung, 
Testierung weiterer Inhibitoren mit abweichenden chemischen Strukturen, 
Microarray- und Gene Ontology-Analysen, Untersuchungen zur Struktur-
Aktivitätsbeziehung und IC50-Wertbestimmungen. Die weitere Erforschung 
des Wirkmechanismus und die Zielvalidierung umfassten biochemische 
Testverfahren, wie Westernblot, genetische Knock-down-Experimente, und in 
vivo phänotyp-basierte Testverfahren am Zebrafischmodell.  
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8.4 Ergebnisse 
 
Ich entwickelte ein Testverfahren (screening assay) in 96-Well-
Mikrotiterplatten basierend auf der unterschiedlichen Exprimierung des OCT4-
GFP-Reportergens in GOF18 EpiS-Zellen und ES-Zellen für die 
Identifizierung von aktiven niedermolekularen Verbindungen (small 
molecules). Für die Auslese wurde ein High-content-Lesegerät für 
Mikrotiterplatten verwendet. Ich identifizierte Triamteren (TR), ein bekanntes 
Pteridinderivat, das als Diuretikum verwendet wird, als Trefferverbindung. Die 
Validierung der Trefferverbindung zeigte, dass TR mehrere EpiS-Zelllinien 
des späten Stadiums in einen Zustand konvertieren konnte, der viele 
Eigenschaften mit ES-Zellen teilte. Die konvertierten Zellen waren jedoch 
nicht in der Lage, zur Entwicklung von Chimären beizutragen, wenn sie in 
Blastozysten injiziert wurden. Dieses Defizit konnte durch die Ergänzung der 
TR-induzierten Konvertierung durch gleichzeitige Inhibition des ERK-
Signalwegs überwunden werden, was in der Gewinnung von ES-Zell-
ähnlichen Zellen mit vollständiger Chimärenkompetenz resultierte. 
Kinaseprofilierung identifizierte CK1!/" und PI3Kclass2% als mögliche 
Zielmoleküle von TR. Anschließende Gen-knock-down-Experimente 
bestätigten die Isoform CK1" als das Zielmolekül der TR-induzierten 
Konvertierung. Untersuchungen der Struktur-Aktivitätsbeziehung führte zur 
Synthese eines deutlich potenteren Inhibitors, genannt AU52, mit der 
Fähigkeit der naiven Zellkonvertierung. Biochemische Analysen zeigten, dass 
die Inhibition von CK1" in der gleichzeitigen Inhibition der Phosphorylierung 
von #-CATENIN and SMAD2 resultierte. Die zeitgleiche Stimulierung des 
WNT und Blockierung des TGF# Signalwegs führten zur Aktivierung der ES-
Zell-spezifischen Transkriptionsfaktoren Klf2, Nanog und Esrrb, die schließlich 
die naive Konvertierung bewerkstelligten. 
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8.5 Schlussfolgerung 
 
Zusammenfassend stellen die vorliegenden Ergebnisse das erste chemische 
Protokoll für die Reprogrammierung von EpiS-Zellen des späten Stadiums in 
naive Pluripotenz dar. Ich zeige, dass CK1" einen Einfluss auf das 
Kernnetzwerk der Regulierung des Grundzustands der Pluripotenz hat, und 
erläutere den Wirkmechanismus der TR/AU52-induzierten naiven 
Konvertierung. Letztendlich stelle ich eine neue chemische Methode für die 
weitere Erforschung der zwei Stadien der "naïve" und "primed" Pluripotenz 
vor. !
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9. Appendix 
 
 
Appendix 1. Kinase Profiling of Triamterene and AU52 Against a 
Selected Set of ESC-Related Kinases 
 
 Residual kinase activity [%] 
Kinase TR @ 10$M  AU52 @ 10 $M 
Abl 98 92 
Abl (m) 97 91 
Akt1  100 102 
Akt2  112 94 
Akt3 95 71 
ALK  86 79 
ALK4  93 86 
ALK5  107 102 
Aurora A 103 66 
Aurora B 101 98 
Aurora C  90 86 
CDK1/cyclinB  103 101 
CDK2/cyclinA  103 100 
CDK2/cyclinE  101 85 
CDK3/cyclinE  96 97 
CDK5/p25  97 85 
CDK5/p35  103 86 
CDK6/cyclinD3 93 98 
CDK7/cyclinH/MAT1 86 139 
CDK9/cyclin T1 87 101 
CK1#1 98 86 
CK1#2  95 85 
CK1#3  110 90 
CK1$  28 -7 
CK2  95 86 
CK2"2 109 79 
cSRC 97 102 
FAK  105 105 
Fer  111 96 
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Appendix 1 cont. 
 
FGFR1 93 116 
FGFR2 104 93 
FGFR3 99 84 
FGFR4 99 100 
GSK3-alpha  102 95 
GSK3-beta 114 95 
IKK-alpha  103 96 
IKK-beta  93 71 
JAK2 94 104 
JAK3 118 86 
JNK1"1 104 101 
JNK2"2 102 89 
JNK3 90 59 
LIMK1  89 92 
Lyn  88 86 
Lyn (m) 97 103 
MAPK1 115 84 
MAPK2 108 94 
MAPK2 (m) 102 90 
MAPK12  107 93 
MAPK13 87 76 
MEK1 107 117 
MKK4 (m) 129 120 
MKK6  108 111 
MKK7-beta  114 135 
MLCK 89 82 
MLK1 88 71 
MST1  101 99 
MST2  99 85 
MST3 102 89 
mTOR 83 94 
NLK  93 84 
p38 alpha  100 93 
p38 beta  92 89 
p70S6K  91 94 
PAK2  107 103 
PAK4  94 103 
PAK5  100 82 
PAK6  89 85 
PDK1  103 83 
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Appendix 1 cont. 
 
PI3 Kinase (p110b/p85a) 100 93 
PI3 Kinase (p120g) 58 60 
PI3 Kinase (p110d/p85a) 81 51 
PI3 Kinase (p110a/p85a) (m) 89 90 
PI3 Kinase (p110a/p65a) (m) 91 90 
PI3 Kinase (p110a(E545K)/p85a) (m) 91 82 
PI3 Kinase (p110a(H1047R)/p85a) (m) 96 91 
PI3 Kinase (p110b/p85b) (m) 98 88 
PI3 Kinase (p110b/p85a) (m) 97 90 
PI3 Kinase (p110d/p85a) (m) 60 66 
PI3 Kinase (p110a(E542K)/p85a) (m) 89 83 
PI3 Kinase (p110a/p85a) 82 79 
PI3 Kinase (p110a(E542K)/p85a) 81 91 
PI3 Kinase (p110a(H1047R)/p85a) 81 95 
PI3 Kinase (p110a(E545K)/p85a) 75 84 
PI3 Kinase (p110a/p65a) 86 87 
PI3KC2a 107 76 
PI3KC2g 35 23 
PKA  103 104 
PKC" 110 88 
PKC!I 101 98 
PKC!II 93 90 
PKC# 103 102 
PKC$ 107 93 
PKC% 106 87 
PKCµ 106 88 
PKC' 105 95 
PKC& 102 86 
PKCµ 100 96 
PKC* 107 97 
PKC+ 123 100 
PIP4K2a 98 86 
PIP5K1a 95 87 
PIP5K1g 76 73 
ROCK-I 105 80 
ROCK-II  100 102 
Src(1-530) 96 94 
Syk  92 89 
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Appendix 2. Primer Sequences for qRT-PCR 
 
Gene Fwd primer 5'-3' 
Rev primer 
5'-3' 
Axin2 TAGGCGGAATGAAGATGGAC CTGGTCACCCAACAAGGAGT 
beta-
Act ACTGCCGCATCCTCTTCCTC CCGCTCGTTGCCAATAGTGA 
Cdx1 GGGGTCACTGTGGACAAACT GGCCTAGGACACAAGAGCTG 
Dppa4 CGGGCGTCATAACCAGTTCA GACATGCATGCGGAGGCTAC 
Dppa5 TGTGTCTCCGACCTGGATGC CACATCAGAATGCGCAGCAG 
Esrrb AGGCTCTCATTTGGGCCTAGC ATCCTTGCCTGCCACCTGTT 
Fgf5 CCTTGCGACCCAGGAGCTTA CCGTCTGTGGTTTCTGTTGAGG 
Fgf8 TCGCGAAGCTCATTGTGGA GCCGTTGCTCTTGGCAATTAG 
Gapdh CCAATGTGTCCGTCGTGGAT TGCCTGCTTCACCACCTTCT 
Klf4 TGTGTCGGAGGAAGAGGAAGC ACGACTCACCAAGCACCATCA 
Nanog GAACGGCCAGCCTTGGAAT GCAACTGTACGTAAGGCTGCAGAA 
Oct4 TGTTCCCGTCACTGCTCTGG TTGCCTTGGCTCACAGCATC 
Rex1 GGCTGCGAGAAGAGCTTTATTCA AGCATTTCTTCCCGGCCTTT 
Sox1 GGCCGAGTGGAAGGTCATGT TCCGGGTGTTCCTTCATGTG 
Sox2 TTCGAGGAAAGGGTTCTTGCTG TCCTTCCTTGTTTGTAACGGTCCT 
Stella 
(Dppa3) GCCGCACAGCAGATGTGAA AAATCTGGATCGTTGTGCATCCT 
T TTGAACTTTCCTCCATGTGCTGA TCCCAAGAGCCTGCCACTTT 
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10.  Abbreviations 
 
 
°C  degree Celsius 
µg  microgram 
µl  microliter 
µM  micromolar 
2i  PD0325901 and CHIR99021 
ALP  alkaline phosphatase 
AP  alkaline phosphatase 
bFGF  basic fibroblast growth factor; also FGF2 
BIOS  biology-oriented synthesis 
BMP4  bone morphogenetic protein 4 
BSA  bovine serum albumin 
cDNA  copy deoxyribonucleic acid 
CH  CHIR99021 
cm  centimeter 
CM  conditioned medium 
CRISPR clustered regularly interspaced short palindromic repeats 
Ctrl  control 
Da  Dalton 
DE  distal enhancer 
DMEM Dulbecco's Modified Eagle's Medium 
DNA  deoxyribonucleic acid 
DOS  diversity-oriented synthesis 
dpc  days post coitum; also E3.5 
E3.5  embryonic day 3.5; also 3.5 dpc 
ENaC  epithelial sodium channel 
EpiSC  epiblast stem cell 
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FCS  fetal calf serum 
FGF2  fibroblast growth factor 2; also bFGF 
FRET  fluorescence resonance energy transfer 
GFP  green fluorescent protein 
GO  gene ontology 
GPCR  G protein-coupled receptor 
H&E  hematoxylin and eosin stain 
hESC  human embryonic stem cell 
hpf  hours post fertilization 
HRP  horseradish peroxidase 
hrs  hours; also hr 
HTRF  homogeneous time resolved fluorescence 
ICM  inner cell mass 
ID  identification 
KD  knockdown 
KOSR  knockout serum replacement 
LIF  leukemia inhibitory factor 
MEF  mouse embryonic fibroblasts 
mESC  mouse embryonic stem cell 
mg  milligram 
min  minute 
ml  milliliter 
mm  millimeter 
mM  millimolar 
ng  nanogram 
NMR  nuclear magnetic resonance 
PBS  phosphate buffered saline 
PD  PD0325901 
PE  proximal enhancer 
PFA  paraformaldehyde 
PSSC  protein structure similarity clustering 
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PVDF   polyvinylidene difluoride 
qRT-PCR  quantitative reverse transcription polymerase chain  
   reaction 
RNA   ribonucleic acid 
rpm   revolutions per minute  
RT   room temperature 
SAR   structure-activity-relationship 
SB   SB431542 
SCONP  structural classification of natural products  
SD   standard deviation 
SDS-PAGE  sodium dodecyl sulfate polyacrylamide gel   
   electrophoresis 
shRNA  short hairpin ribonucleic acid 
SILAC   stable isotope labeling by/with amino acids in cell culture 
TALEN  transcription activator-like effector nucleases  
TBST   tris buffered saline with Tween 20 
TOS   target-oriented synthesis 
TR   Triamterene 
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